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ABSTRACT 
This thesis tests the hypothesis that certain inflammatory mediators, including kinins 
and cytokines are involved in sensitisation of peripheral nociceptors and contribute to 
the hyperalgesia associated with inflammatory conditions. These studies involved the 
development of a new model for recording from C- fibres innervating the rat knee joint 
and determined the role of these substances and their interactions in modulating neural 
discharge from articular nociceptors. Complementary behavioural studies were 
carried out to assess the role of these mediators in thermal and mechanical 
hyperalgesia. 
Recordings from C- fibres innervating the medial side of the rat knee joint revealed 
that Bk induced an increase in neural discharge in normal and arthritic knee joints 
which was blocked by a kinin B2 receptor antagonist, icatibant. desArg9 -Bk was 
ineffective in normal joints, however in arthritic joints desArg9 -Bk induced an 
increase in neural discharge in C- fibres which was mediated via kinin B1 receptors, as 
it was reduced by desArg9leu8 -Bk, but not icatibant. 
IL -i3 injected into the knee joint induced an increase in neural discharge from C- 
fibres which was blocked by concomitant injection of IL- lra. This was consistent 
with behavioural studies where local injection of IL -113 induced a mechanical and 
thermal hyperalgesia. IL -113 also enhanced responses mediated by Bk in C- fibres and 
in mechanical hyperalgesia. In the mechanical hyperalgesia model the enhanced 
responses to Bk were blocked by both desArg9leu8 -Bk and icatibant. IL -1 f3 was also 
shown to be involved in inducing a desArg9 -Bk- mediated increase in neural discharge 
in C- fibres and a desArg9 -Bk- mediated behavioural hyperalgesia (mechanical and 
thermal). The desArg9 -Bk mediated hyperalgesia was blocked by desArg9leu8 -Bk, but 
not icatibant. 
Pre -treatment with indomethacin blocks IL -1(3- induced increase in neural discharge 
and behavioural hyperalgesia. Indomethacin also blocks IL -1(3- induced enhancement 
of Bk- mediated increase in neural discharge from C- fibres and IL -113- induced 
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enhancement of Bk- mediated mechanical hyperalgesia. Although indomethacin 
blocked the kinin-B1-mediated increase in neural discharge induced by IL -1(3, 
indomethacin did not reduce the kinin B1- mediated mechanical hyperalgesia induced 
by IL -113 and only blocked the kinin BI-mediated thermal hyperalgesia induced by IL- 
113 for one hour. 
These studies also considered the involvement of mediators which are increased 
during inflammation in modulation of C -fibre activity and behavioural hyperalgesia. 
The role of endogenous nitric oxide in modulating neural discharge of C- fibres was 
studied in normal and arthritic ankle joints. L -NAME, a nitric oxide synthase 
inhibitor, induced an increase in neural discharge from articular C- fibres in both 
normal and arthritic ankle joints and increased Bk- mediated increase in neural 
discharge in arthritic ankle joints. These effects were reduced by L- Arginine, a nitric 
oxide precursor. L- Arginine itself reduced Bk- mediated increase in neural discharge 
in both normal and arthritic ankle joints. The role of two `anti -inflammatory' 
cytokines (IL -4 and IL -10) in modulating behavioural hyperalgesia was also studied. 
IL -4 and IL -10 reduced IL -1f3- induced mechanical hyperalgesia and thermal 
hyperalgesia, however the duration of action of IL -10 (less than 2h) was shorter than 
IL -4 (at least 5h) in the thermal hyperalgesia model. IL -4 and IL -10 also blocked IL- 
1[3-induced enhancement of Bk- mediated and desArg9 -Bk- mediated mechanical and 
thermal hyperalgesia, however once again, the duration of action of IL -10 (less than 
2h) was shorter than IL -4 (at least 5h). 
In conclusion, the results illustrate a role for both kinin B2 and B1 receptors in 
modulating neural discharge from knee joint C- fibres and hyperalgesia in 
inflammation. 1L -113 is involved in modulating neural discharge from articular C- 
fibres and modulation of kinin- mediated modulation of neural discharge which 
appears to involve generation of prostanoids in the case of enhancement of Bk- 
mediated responses. These results also highlight a role for IL -4, IL -10 and nitric oxide 
as mediators which potentially limit the hyperalgesia associated with inflammation. 
Overall, the present results add further to our knowledge and understanding of the 
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peripheral mechanisms involved in inflammatory pain. 
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1. INTRODUCTION. 
1.1 Pain and Nociception 
The sensation of pain is the body's conscious appreciation of stimuli of such an intensity or 
nature that they threaten the integrity of tissues. The existence of a neural mechanism that 
detects potential tissue damage or injury was postulated at the beginning of the century 
(Sherrington, 1906), based on this concept these pain sensors were termed nociceptors. 
Following this, several groups identified a sub -group of primary afferents in the skin, muscles 
and joints which respond to mechanical and thermal stimuli outside the normal physiological 
range (Bessou & Perl, 1969; Van Hees & Gybels, 1972; Mense, 1985; Schaible & Schmidt, 
1984). Since these extensive studies, Sherrington's definition has been updated. Many 
nociceptors are activated by agents, including kinins which do not necessarily cause tissue 
damage and can act for long periods when released endogenously. Thus, pain exists long after 
the potentially damaging stimulus has been removed and it has since been suggested that pain 
acts as an `adjunct to protective reflexes' (McMahon & Koltzenburg, 1990). Nociceptors 
have been classified according to: their response to different modalities of intense stimuli, 
conduction velocity (CV), and differences in their characteristic response to chemical stimuli 
(Raja et al., 1988). Although nociceptors are present in a variety of tissues and organs, 
including skin, muscle, eye etc, the main focus of the present study is on nociceptors 
innervating articular joints. 
In the naive knee joint these have been categorised into the following four groups (Schaible & 
Schmidt., 1983): 
Group I : Nerves excited by innocuous movement (CV: > 60 ms-1 ). 
Group II : Nerves only weakly excited by innocuous movement, while noxious 
movement leads to pronounced neural discharge(CV: 21 - 60ms -I). 
Group III : Nerves that respond consistently only to noxious join movements 
(CV: 2.5 - 20 ms -1). 
Group IV : Nerves that cannot be excited by any joint movement (CV: < 2.5 ms -1). 
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The majority (70 %) of thin myelinated (AS -) and unmyelinated (C -) fibres belong to groups III 
and IV (Schaible & Grubb, 1993). The discovery that capsaicin, a derivative of capsicum (red 
peppers) could selectively activate C- fibres has been of great use in the study of pain, allowing 
the selective stimulation, and therefore identification of nociceptors (Szolcsanyi et al., 1988). 
Pain can be classified into two distinct types. The first is protective or physiological pain, 
which is elicited by intense stimuli and serves to protect against potential damage to the 
tissue. The second is clinical pain, which accompanies an underlying pathology. For 
example, pain arises due to tissue injury in the case of inflammatory pain, or as a consequence 
of disturbances to the nervous system in the case of neuropathic pain (see Woolf, 1987). 
Treatment of these two types of clinical pain also highlights differences. Conventional 
analgesics including opiates and NSAIDs are, in general, ineffective or show reduced efficacy 
in neuropathic pain when compared to inflammatory pain (for review see Fields, 1994). 
1.1.1 Hyperalgesia 
Hyperalgesia is defined as `a state of increased pain sensation induced either by noxious or 
ordinarily non -noxious stimulation of peripheral tissue' and is characterised by increased 
sensitivity to mechanical or thermal stimuli (Hardy et al., 1952). This can be further 
subdivided into primary hyperalgesia which occurs at the site of injury and secondary 
hyperalgesia which occurs in the surrounding undamaged tissue (Campbell et al., 1989). For 
example, during a hyperalgesic state groups III and IV afferents become sensitised and are 
activated by lower mechanical thresholds than normal. 
Discovering how nociceptors become sensitised and what produces this sensitisation has been 
of great interest and advantageous in helping the understanding of hyperalgesia. The fact that 
hyperalgesia accompanies inflammation and inflammatory diseases (including joint pain in 
arthritis) has led to the study of inflammatory mediators associated with the sensitisation of 
nociceptors. There is a myriad of mediators released during inflammation and these mediators 
have many actions and interactions with each other. It is, therefore, questionable as to the 
physiological value of studying these mediators separately. However, investigating them 
individually has advanced the understanding of peripheral hyperalgesia and the sensitisation 
of nociceptors. Several inflammatory mediators have been identified as having sensitising 
10 
effects on nociceptors including bradykinin, prostaglandins, 5- hydroxytryptamine (5 -HT) and 
cytokines (bradykinin and cytokines will be discussed in more detail in the Sections 1.3.1 and 
1.3.2). 
Prostanoids, in particular PGE1, PGE2 and PGI2, have been shown to be more involved in 
sensitisation of nociceptors rather than excitation. When injected intra- articularly into the cat 
knee joint, PGE1 and PGE2 sensitised nociceptors to movement of the joint (Heppelmann et 
al., 1985; Schaible & Schmidt, 1988). Similarly, in the rat ankle joint PGE2 has been shown 
to sensitise nociceptors to mechanical stimulation and other algesic agents e.g. bradykinin 
(Birrell et al., 1991). However, PGI2 has a much greater role in sensitisation of nociceptors; 
in the rat ankle joint PGI2 and the more stable agonist cicaprost sensitised the majority of 
nociceptors (80 - 90 %) to mechanical stimulation (Birrell et al., 1991). 5 -HT which is also 
released during inflammation, mainly from mast cells, has been shown to excite and sensitise 
group III (43 %) and IV (73 %) afferents to mechanical stimuli in both the cat knee joint and rat 
ankle joint (Herbert & Schmidt, 1992; Birrell et al., 1990) probably via 5 -HT3 receptors. 
There is some evidence that leukotrienes (LT's), in particular LTB4 can also sensitise 
peripheral nociceptors to mechanical stimulation (Martin et al., 1987). Thus, there is the 
capacity for a range of inflammatory mediators to sensitise nociceptors resulting in 
hyperalgesia. 
1.1.2 Animal models of pain 
Animal models are widely used to further the understanding of pain mechanisms due to the 
limitations of what can be undertaken in human experiments. The models used can be 
categorised as either acute or persistent. Acute models include tail flick, hot plate, limb - 
withdrawal reflex and vocalisation thresholds, and use an exogenously applied stimulus (heat 
or pressure) to excite nociceptors directly. Persistent models are usually associated with a 
long lasting or chronic inflammation, which alters the local environment around the 
nociceptors and maintains a persistent state of hyperalgesia (Rang et al., 1991). Persistent 
pain models may be more relevant in studying the mechanisms underlying the hyperalgesia 
associated with chronically painful clinical disorders such as arthritis and gout. In these 
models animals, respond to stimuli, whether thermal, mechanical or chemical, with an 
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increased sensitivity. 
One animal model which has been used extensively to study the mechanisms underlying 
chronic pain is the polyarthritic rat, in which arthritis is induced by injection of Freund's 
complete adjuvant (FCA). Newbould (1963) described an arthritic syndrome induced by 
intradermal injection of 0.05m1 of 5mgm1 -1 of dead tubercle bacilli into the plantar surface of 
the rat hind paw and the subsequent development of arthritis was measured in terms of 
increase in foot thickness. However, although this produces arthritis in the joints and an 
associated hyperalgesia (Guilbaud et al., 1985), it is a very severe model and induces a 
systemic disease which includes skin lesions, destruction of bone and cartilage and 
impairment of liver function (Coderre & Wall, 1987). Less severe models, as well as being 
ethically more acceptable, may be more appropriate for nociceptive studies and models have 
been developed which involve localised administration of substances to elicit inflammation 
and hyperalgesia. The original method of Newbould (1963) has been developed and modified 
to induce a localised unilateral arthritis. 
Persistent mechanical hyperalgesia can be observed and studied following intra- plantar 
injection of carrageenin, kaolin and Freund's complete adjuvant using the Randall -Selitto paw 
withdrawal test (Randall & Selitto, 1957). These agents produce a localised inflammation 
leading to a decreased withdrawal threshold to mechanical stimuli. To study the mechanisms 
of pain that mimics the clinical conditions of arthritis, joint pain can be induced in animals by 
injection of pro -inflammatory agents including urate crystals or Freund's complete adjuvant 
either around the joint or directly into the joint space. In these models the hyperalgesia which 
develops is evidenced by a reduced threshold tolerated by movement of the joint or pressure 
applied to the joint (Coderre & Wall, 1987; Grubb et al., 1988; Grigg et al., 1986; Perkins et 
al., 1993). Some of these studies are purely behavioural, whereas others involve recording the 
activity of C- fibres innervating the joints as an indication of pain sensation. The posterior 
articular nerve (PAN) and medial articular nerve (MAN) which innervate the cat knee joint 
and the primary articulocutaneous ramus (PACR) which innervates the rat ankle joint have 
been recorded from for this purpose. In these studies it was observed that there was little or 
no spontaneous neural discharge in nerves innervating normal joints however, nerves 
innervating inflamed joints had an ongoing spontaneous neural discharge (Grigg et al., 1986; 
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Birrell et al., 1990) and were activated with lower mechanical thresholds or usually non - 
noxious movements. 
To study the differences and similarities between mechanical and thermal hyperalgesia a 
model for studying persistent thermal hyperalgesia model has been developed. Following 
exposure of the plantar surface of the rat paw to ultra -violet irradiation, the treated paw 
showed a reduction in latency to radiant heat directed at the plantar surface of the paw 
(Perkins et al., 1993). 
In all these models there is an associated inflammation. To study the role of individual 
inflammatory mediators in the subsequent hyperalgesia, specific putative inflammatory 
mediators instead of the more non -specific pro -inflammatory agents may be injected locally. 
In this way a link may be established between inflammation and hyperalgesia, and therefore 
advances may be made in the understanding and treatment of pain in the clinic. 
1.2 Inflammation. 
Inflammation consists of a complex series of events which in general terms may be defined as 
the response of living tissue to trauma or infection. It comprises four main stages : local 
vasodilation resulting in increased blood flow to the affected area; contraction of endothelial 
cells resulting in increased vascular permeability and thus leakage of plasma from the micro - 
circulation into the surrounding tissue; migration of polymorphonuclear leukocytes to the site 
of inflammation; and subsequent phagocytosis of immune cells and further release of 
inflammatory mediators (Evans & Whicher, 1992). To be considered an inflammatory 
mediator a substance should satisfy the following criteria : it must be present in elevated 
levels during the inflammatory response; when administered it must induce one or more 
components of the inflammatory response, and antagonists to the mediator should have anti - 
inflammatory activity. 
1.3 Inflammatory mediators. 
There is a plethora of mediators involved in the inflammatory process including histamine, 5- 
hydroxytryptamine, platelet activating factor (PAF), components of the complement system, 
prostanoids, leukotrienes, neuropeptides, kinins, cytokines and nitric oxide. They are 
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involved in a complex series of actions and interactions. However, for the purpose of this 
thesis I have concentrated on kinins, cytokines, prostanoids and nitric oxide. 
1.3.1 Kinins 
1.3.1.1 Formation 
Kinins are formed by the action of proteolytic enzymes termed kallikreins. There are two 
different kallikreins, plasma kallikrein and tissue kallikrein, both of which exist as inactive 
forms called plasma pre -kallikrein and tissue prokallikrein and are synthesised in the liver. 
Plasma pre -kallikrein, a single chain glycoprotein, which is present in the plasma complexed 
with high molecular weight (HMW)- kininogen (Mandle et al., 1976) and on the external 
surface of neutrophils, along with HMW- and low molecular weight kininogen (LMW) - 
kininogen (Figueroa et al., 1992), is activated by Hageman factor. Hageman factor itself is 
activated by negatively charged surfaces, plasma kallikrein and active Hageman factor. 
Tissue prokallikrein is activated by immunological reactions, plasma kallikrein, plasmin and 
autolysis. Tissue kallikrein, a single chain acidic glycoprotein, is more widely distributed in 
tissues: including kidney, pancreas, intestine, salivary glands, synovial tissue (Nustad et al., 
1975; Zeitlin & Smith 1973; Sharma et al., 1983) and in polymorphonuclear leukocytes, 
particularly neutrophils (Figueroa et al., 1989). Following activation, kallikreins act on 
kininogens to release the active kinin fragments; there are two main kininogens, HMW- 
kininogen and low molecular weight (LMW)- kininogen. Both are encoded by a single gene, 
but the HMW- kininogen has six domains whereas the LMW- kininogen has five (Muller - 
Esterl et al., 1986). Plasma kallikrein acts on high molecular weight HMW- kininogen to 
cleave proteolytically releasing the nonapeptide bradykinin (Bk : Arg- Pro -Pro -Gly- Phe -Ser- 
Pro -Phe -Arg). Generally, tissue kallikrein acts on LMW- kininogen to cleave and release 
kallidin (KD : Lys -Arg- Pro -Pro -Gly- Phe -Ser- Pro -Phe -Arg) apart from the mouse and rat 
where the enzyme releases Bk from LMW- kininogen. However, in- vitro, tissue kallikrein can 
release kinins from both HMW- and LMW- kininogen (Iwanaga et al., 1977; Girolami et al., 
1986). In the rat however, tissue kallikrein does not release KD; Okamoto & Greenbaum 
(1983) discovered a rat specific LMW -kininogen (T- kininogen) which was resistant to 
kallikreins but released Ile- Ser -Bk (T- kinin) after hydrolysis with high concentrations of 
14 
trypsin. T- kininogenase, endopeptidase K and an acid proteinase all release T -kinin from T= 



























The kallikrein -kinin forming system. 
T-Kininogen 
Bradykinin T-kinin 
Broken lines signify a substance which activates another, solid lines show substances which 
act on other substances to produce or release others. 
1.3.1.2 Degradation 
Kinins are often termed autacoids (local hormones) due to their localised action and rapid 
breakdown. Indeed, they are almost completely degraded (90 - 95%) after one pass through 
the pulmonary vascular bed (Ferreira & Vane, 1967). The half -life of Bk is approximately 
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one minute in plasma. There are two main kinin degrading enzymes (kininases), kininase I 
(carboxypeptidase N) which cleaves the terminal Arginine to form desArg9 -Bk or desArg10- 
KD and kininase II (angiotensin converting enzyme) which liberates the Phe8 -Arg9 dipeptide. 
Kinins can then be further degraded to liberate smaller inactive peptide fragments by neutral 
endopeptidase, aminopeptidase P and post proline cleaving enzyme as illustrated in Figure 
1.2. 
T -kinin is broken down in serum by two catalytic steps to desArg9 -Bk. A leucine 
aminopeptidase liberates the dipeptide Ile -Ser and carboxypeptidase N removes the terminal 
Arginine (Rehbock et al., 1992). DesArg9 -Bk is then further degraded to inactive peptide 
fragments as described above. 
Aminopeptidase P 
Neutral Endopeptidase P 









The arrows show the site of action of degrading kinin enzymes for the breakdown of Bk and 
KD (underlined). 
1.3.1.3 Receptors 
Kinin receptors have been classified according to the relative potencies of agonists and 
antagonists. Two main classes of receptor were found by studies in -vitro on smooth muscle 
preparations from the rabbit, namely the aorta and the jugular vein. These have been termed 
kinin B1 ( Regoli et al., 1977a) and B2 receptors respectively (Regoli et al., 1977b). Kinin B2 
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receptors, although they differ slightly between species, generally exhibit the following rank 
order of potency (Regoli et al., 1993): 
KD > Bk > T-kinin > desArg10-KD > desArg9-Bk 
Many of the effects of Bk, in -vitro and in -vivo, are mediated through interaction with the B2 
receptor. The kinin B, receptor generally exhibits a rank order of potency which is almost 
directly the inverse to that of the B2 receptor (Regoli et al., 1993): 
desArg10-KD > desArg9-Bk > KD > Bk > T-kinin 
In general terms, B1 receptors show a much greater affinity for the kininase I metabolites of 
KD and Bk, desArg10 -KD and desArg9 -Bk. For example, the B1 receptor exhibits a 10- to 50- 
fold preference for desArg9 -Bk over Bk. 
The B2 receptor is present in normal tissue, whereas the B 1 receptor is not expressed to any 
significant level in normal tissues. Responses to a B1 agonist, desArg9 -Bk, increase over time 
in the rabbit aorta (Regoli et al., 1977). This increase in BI- mediated contraction could be 
inhibited by continuous exposure of tissues to dexamethasone a steroidal anti -inflammatory 
agent, suggesting a role for immunocompetent cells (Deblois et al., 1988). BI- mediated 
responses may also be induced by agents which produce an inflammatory response, such as 
LPS or inflammatory mediators, including interleukin 113 (Bouthillier et al., 1987). This 
induction or up- regulation of receptors is probably due to de novo synthesis, as it can be 
blocked by the protein synthesis inhibitor, cyclohexamide (De Blois et al., 1991). 
Development of selective kinin receptor antagonists has furthered the understanding of the 
kinin receptor classes. Substitution of amino acid residues in the kinin structure led to the 
development of what are termed first generation antagonists. A selective kinin B 1 antagonist 
was developed by substituting a leucine amino acid residue at position 8 of the desArg9 -Bk 
peptide to give desArg9[leu8] -Bk. This antagonist was active in the rabbit aorta against 
desArg9 -Bk, but was inactive in the rabbit jugular vein against Bk ( Regoli et al., 1977). The 
first kinin B2 antagonist, [D- Phe7] -Bk, involved replacement of the proline residue at position 
7 with the D- enantiomer of phenylalanine (Vavrek & Stewart, 1985). Incorporation of D- 
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phenylalanine at this position yields a peptide which is resistant to degradation by kininase II 
(Togo et al., 1989). Extension of the peptide at the N- terminus by adding a D- Arginine 
residue prevents the action of aminopeptidase N (Stewart, 1992). Further amino acid residue 
substitutions have yielded antagonists with a greater affinity, which are more selective for the 
B2 receptor. The best of these, with respect to affinity and selectivity, is D- Arg[Hyp3,D- 
Phe7,Leu8 } -Bk which has a pA2 of almost 8.9 in the rabbit jugular vein compared to 5.8 in the 
rabbit aorta. Development of what are termed the second generation antagonists has increased 
the selectivity of antagonists for the B2 receptor. The first of these was the Hoechst antagonist 
HOE 140, which has since been named icatibant. Hock et al. (1991) modified the D- 
phenylalanine at position 7 and the proline at position 8 to give a peptide which contained two 
synthetic amino acid residues and which was resistant to enzymatic degradation : D- 
Arg[Hyp3,Thi5,Tic7,Oic8] -Bk. This antagonist had a pA2 in the rabbit jugular vein of 9.2 and 
was inactive on the rabbit aorta against desArg9 -Bk. Removal of the terminal Arginine 
converted icatibant into a selective B1 receptor antagonist desArg10 -HOE 140 (Wirth et al., 
1991). 
The apparent differences in potency of these antagonists in different tissues has led several 
groups to suggest that there may be several sub -types of the B2 receptor. For example D- 
Arg[Hyp3,D- Phe7,Leu8] -Bk has a pA2 value of 8.9 in the rabbit jugular vein compared to 6.8 
in the guinea pig ileum, which led to a proposal that different subtypes of the B2 receptor were 
present in the different tissues: B2A in the rabbit jugular vein and B2B in the ileum. However, 
icatibant was shown to have an equally high affinity in both preparations suggesting that the 
difference may be species dependent (Regoli et al., 1992). 
Farmer et al. (1989) have suggested a third class of kinin receptor which they identified on 
guinea -pig tracheal smooth muscle. They found that two B2 receptor antagonists, D- 
Arg[Hyp3,D- Phe7] -Bk and D- Arg[Hyp3,D- Phe7,Leu8] -Bk, and the B1 receptor antagonist, 
desArg9[leu8] -Bk, were unable to block Bk- induced contractions of tracheal smooth muscle. 
They suggested the presence of a new class of receptor which they called the B3 receptor. 
However, this suggestion has been questioned after Hock et al. (1991) found that icatibant 
blocked the effect of Bk in the isolated guinea pig trachea. Icatibant contains strong 
hydrophobic residues that improve occupation of the receptor in different species (Regoli et 
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al., 1992). 
Although the development of these second generation antagonists has led to discovery of 
increasingly more potent and biologically active antagonists, they are all peptides and thus 
subject to metabolism (with the exception of HOE 140) and poor bioavailability (Ward, 
1990). The development of a non -peptide kinin antagonist was considered an important 
advance. Sawutz et al. (1994) discovered the first non -peptide potent antagonist, [[4 -[[2- 
[ [bis(cyclohexylamino)methylene] amino] -3 -(2- (napthyl) -1 oxopropyl] amino]phenyl]methyl] 
tributylphosphoniumchloride monohydrochloride (WIN 64338), which was selective for the 
B2 receptor. More recently, Asano et al. (1997) identified an orally active non -peptide 
antagonist, which was selective for the kinin B2 receptor. (E)-3-(6- acetamido- 3- pyridyl) -N- 
[2-4- dichloro- 3 -[(2- methyl- 8- quinolinyl)oxymethyl] phenyl] -N- methylaminocarbonylmethyl] 
acrylamide (FR173657) inhibited Bk- induced bronchoconstriction in the guinea pig following 
oral administration, with an ED50 of 0.075mgkg 1. FR173657 was also shown to be as potent 
as icatibant and was active at the human B2 receptor. 
Table 1.1. Summary table of pA2 values of kinin antagonists in different smooth muscle 










[D- Phe7] -Bk 5.94 - - 
D- Arg[Hyp3,D- Phe7,Leu8] -Bk 5.76 8.9 6.77 
Icatibant inactive 9.17 8.94 
WIN 64338 < 4 5.7 8.19 
FR173657 - - 9.2 
desArg9[Leu8] -Bk 7.3 inactive inactive 
desArg10 -HOE 140 7.5 inactive inactive 
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The two classes of receptor have been cloned; the rat B2 receptor was cloned (McEachern et 
al., 1991) and this was followed by the human B2 receptor (Hess et al., 1992). Menke et al. 
(1994) have since cloned the human B1 receptor: the mRNA coding for the B1 receptor which 
co- existed with the mRNA coding for the B2 receptor, but was significantly shorter than the 
B2 mRNA (Webb et al., 1994). The B1 receptor has 36% homology with the kinin B2 receptor 
(Menke et al., 1994). Although both receptors are encoded by different genes, both receptors 
have the seven transmembrane domain structure typical of G- protein coupled receptors. 
Between species the individual receptors are more homologous. At the amino acid level, the 
kinin B2 receptors from rodents (rat and mouse) is 77% homologous to the human receptor 
(Brown et al., 1995). For the B i receptor the homology between rat and human is 72% (Jones 
et al., unpublished data). 
1.3.1.4 Second messengers 
Bk is unusual in the fact that when it binds to the B2 receptor it can activate almost every 
second messenger system, depending on the location of the receptor. On sensory neurones 
when Bk binds to the B2 receptor which is linked to a G- protein, it produces a depolarisation 
due to an increase in membrane permeability to Na+ (Dunn & Rang, 1990; McGuirk & 
Dolphin, 1992). This influx of ions may activate a voltage dependent Ca ++ channel and a 
subsequent influx of Ca + +. Bk also stimulates membrane bound phospholipase C and the 
subsequent generation of inositol 1,4,5 triphosphate (IP3) and diacylglycerol (DAG). IP3 can 
then elevate intracellular Ca ++ by inducing it's release from intracellular stores (Burgess et al., 
1989; Dray & Perkins, 1993). DAG activates intracellular protein kinase C which in turn has 
been shown to inhibit membrane Cat+ conductance (Dray et al., 1988). 
On non -neuronal cells, including fibroblasts, synovial cells and isolated smooth muscle cells, 
Bk acting through a B2 receptor also activates membrane phospholipase A2 resulting in the 
production of prostanoids (Bareis et al., 1983; Burch & Axelrod, 1987; Bathon et al., 1989; 
Galizzi et al., 1994). Prostanoids, acting on prostanoid receptors, can activate adenylate 
cyclase and thereby raise levels of cAMP which in turn inhibits Ca'-dependent K+ 
permeability - which underlies a post -spike hyperpolarisation. This probably underlies the 
mechanism by which prostanoids can sensitise sensory neurones to Bk ( Weinreich, 1986). 
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Apart from rapid enzymatic degradation, there are several other regulatory mechanisms 
involved in Bk activity. Bk releases nitric oxide (NO) from L- Arginine via B2 receptors on 
vascular endothelial cells and subsequent activation of nitric oxide synthase. NO can then 
activate cellular guanylate cyclase to increase intra- cellular cGMP. cGMP then activates 
cGMP -dependent kinases which phosphorylate the kinin B2 receptor, resulting in receptor 
desensitisation (McGehee et al., 1992; Burgess et al., 1989). Desensitisation of the receptor 
may also involve down regulation of receptor number or internalisation of receptor proteins 
(Roberts & Gullick, 1990). 
Although distinctly different from the kinin B2 receptor, many of the second messengers 
involved following B1 receptor activation are the same. Activation of this receptor produces 
an increase in intracellular Ca ++ in smooth muscle cells (Smith et al., 1994; Marsh & Hill, 
1994) and stimulation of membrane bound phospholipase C (Levesque et al., 1993). As with 
the B2 receptor, activation of the B1 receptor activates membrane bound phospholipase A2 
with subsequent release of prostanoids from endothelial cells, smooth muscle cells, fibroblasts 
and macrophages (D'Orleans -Juste et al., 1989; Galizzi et al., 1994; Marceau & Tremblay, 
1986; Tiffany & Burch, 1989; Marceau et al., 1995). 
1.3.1.5 Kinins in inflammation and nociception 
1.3.1.5.1 Involvement of kinin B2 receptors 
Bk has all the properties of an inflammatory mediator. When injected into experimental 
animals and humans it produces inflammation (Marceau et al., 1983), and levels of Bk have 
been shown to be elevated in acute inflammation and several chronic inflammatory diseases 
such as rheumatoid arthritis (Hargreaves et al., 1988; Sharma & Buchanan, 1993). Injection 
of Bk evokes a vasodilation which is mediated both directly through B2 receptors located on 
vascular smooth muscle cells and indirectly by an action on B2 receptors on endothelial cells, 
smooth muscle cells and inflammatory cells to release nitric oxide and prostanoids (Bareis et 
al., 1983; Burch & Axelrod, 1987). In inflammatory conditions, the rapid breakdown of Bk 
by kinases results in vasodilation localised to the site of inflammation. Bk when injected into 
the skin of animals and humans produces a localised oedema by acting on B2 receptors on 
vascular endothelial cells, resulting in an increased vascular permeability and subsequent 
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leakage of plasma and inflammatory cells into the surrounding tissue (Marceau et al., 1983). 
Bk also causes leukocyte accumulation to the site of tissue injury (Lewis, 1970), and binds to 
B2 receptors on certain leukocytes to release further inflammatory mediators, including 
cytokines and prostanoids (Burch & Axelrod, 1987; Tiffany & Burch, 1989). This 
accumulation of leukocytes, some of which contain kallikreins and their substrates, 
kininogens (Figueroa et al., 1992), at the site of tissue injury and inflammation further 
enhances the inflammatory process. 
In inflammatory conditions there is usually an associated hyperalgesia. Bk when administered 
to the human blister base has been shown to be one of the most potent algesic agents known 
(Whalley et al., 1987). B2 receptors have been shown to be localised on sensory neurones in 
the dorsal root (Steranka et al., 1988) and activation of these receptors has been shown to 
excite and sensitise peripheral C- fibres in the cat knee joint (Kanaka et al., 1985). Activation 
of these peripheral sensory neurones can release sensory neuropeptides, including substance P 
and CGRP, and nitric oxide from sensory nerve terminals (Teixeira et al., 1993). These 
sensory neuropeptides cause local vasodilation and an increase in vascular permeability, and 
thus further facilitate the inflammatory process. Furthermore, B2 receptor antagonists are anti - 
nociceptive against the hyperalgesia which accompanies inflammation -induced by carrageenin 
(Costello & Hargreaves, 1989), formalin (Haley et al., 1989), Freund's Complete Adjuvant, or 
UV irradiation (Perkins et al., 1993) and peridontal inflammation (Griesbacher et al., 1994). 
1.3.1.5.2 Involvement of kinin B1 receptors 
Kinin B 1 receptors were originally thought to have a limited role. When B 1 receptor agonists 
were injected into naïve animals there was no inflammation or hyperalgesia produced (Davis 
& Perkins, 1994) and B1 receptor antagonists were inactive at reversing Bk- induced 
inflammation (Marceau et al., 1983). Indeed, evidence for B1 receptors was only observed in 
vascular smooth muscle in particular the rabbit aorta where responses to desArg9 -Bk were 
seen to increase with time (Regoli et al., 1977). However in recent years there has been 
increasing evidence for a role of the kinin B 1 receptor, particularly in inflammatory conditions 
and the accompanying hyperalgesia. B1 receptors and responses can be induced by bacterial 
lipopolysaccharide and inflammatory mediators such as interleukin -1 ß (Deblois et al., 1991). 
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Kininase I activity is also increased in human inflammatory synovial fluid (Chercuitte et al., 
1987) and nasal discharge in allergic rhinitis (Proud et al., 1987). This increased enzyme 
activity would result in an increased breakdown of kinins that are active at B2 receptors to 
metabolites active at B1 receptors. Following treatment of rats with lipopolysaccharide, B1 
receptor agonists were observed to induce an increase in paw oedema, secondary to an 
increase in vascular permeability (Campos et al., 1996). Ahluwalia & Perretti (1996) found 
that following IL -1 13, desArg9 -Bk increased leukocyte accumulation in the mouse air pouch, 
an effect which was reduced by B1, but not B2 receptor antagonists. B1 receptors on 
macrophages have been found to induce the release of inflammatory mediators, in particular 
cytokines (Tiffany & Burch, 1989), thus amplifying the inflammatory process. 
The role of B 1 receptors in the hyperalgesia associated with inflammatory conditions has been 
of great interest in recent years. B1 receptor agonists have been found to be nociceptive in a 
number of inflammatory pain models. Following injection of FCA into the knee B1 agonists 
have been found to be hyperalgesic and antagonists have been found to be anti -nociceptive 
(Davis & Perkins, 1994; Perkins et al., 1993); similar results have been found in UV- induced 
thermal hyperalgesia (Perkins & Kelly, 1993). In the formalin model of hyperalgesia both B1 
and B2 receptor antagonists were reported to be anti -nociceptive (Correa & Calixto, 1993). 
IL -1 ß when injected either into the rat paw or knee joint evokes a B1- mediated mechanical 
hyperalgesia (Ferreira et al., 1988; Davis & Perkins, 1994) or, when injected into the rat paw, 
a B1- mediated thermal hyperalgesia (Perkins & Kelly, 1994). As yet there has been no direct 
evidence of B1 receptors located on sensory neurones. In fact Davis et al. (1996) found no 
evidence of B1 receptors on dorsal root ganglion cells removed from rats which had been pre- 
treated with Freunds complete adjuvant. It therefore seems more likely that B1 receptors are 
induced, or upregulated on non -neuronal cells, such as macrophages, fibroblasts, synovial 
cells, endothelial cells and smooth muscle cells (Tiffany & Burch, 1989; Lerner & Modeer, 
1991; Bathon et al., 1989; Cahill et al., 1988; Galizzi et al., 1994). B1 receptor agonists may 
then act on these cell types to release other pro- inflammatory or algesic agents to potentiate 
the inflammatory response. 
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1.3.2 Cytokines 
Cytokines are a family of soluble proteins or glycoproteins which are produced by leukocytes 
and many other cell types, and generally act as chemical communicators between cells 
(Rothwell & Hopkins, 1995). The cytokine family comprises a range of mediators including: 
interleukins (IL-la, IL -113, IL -2 - IL -14), growth factors, interferons and haematopoietic 
factors. Once released from cells they act on specific receptors on target cells to produce a 
host of actions and interactions with each other, often termed `the cytokine network', and 
other inflammatory mediators, including kinins and prostanoids. To cover all the individual 
actions, interactions and modulations occurring within the cytokine network is outwith the 
scope of this thesis which will concentrate mainly on IL -lß and two anti -inflammatory, or 
modulatory cytokines IL -4 and IL -13. 
1.3.3 Interleukin-1 
1.3.3.1 Formation 
IL -1 consists of two distinct but related glycoproteins, IL- la and IL-1[3, which are encoded by 
separate genes and in most human tissues IL -113 mRNA predominates (Arai et al., 1990). 
Interestingly the gene which encodes IL -1(3 is not spontaneously expressed but can be 
stimulated by LPS, complement components or IL -113 itself to increase production of IL -113 
mRNA rapidly. IL-la and IL -1(3 are synthesised as 31 kD precursors (pro -IL -1) and converted 
to 17.5kD active glycoproteins (Dinarello et al., 1994). Pro -IL -la can be found on the surface 
of cells in a form which is biologically active (Kurt -Jones et al., 1985), whereas pro- IL -113 
requires cleavage for it's optimal secretion and biological activity (Fenton et al., 1988; 
Dinarello, 1994). The enzyme responsible for this is Interleukin converting enzyme (ICE) 
which itself is present in numerous cell types as an inactive precursor (Thornberry et al., 1992; 
Cerretti et al., 1992). In humans IL -la is 26% homologous to its IL -113 relative (Priestle et 
al., 1989; Graves et al., 1990). IL -1 can be produced and released by a variety of cells 
including, macrophages, fibroblasts, keratinocytes, T- and B- lymphocytes, astrocytes, 
microglia, endothelial cells, smooth muscle cells and chondocytes (Callard & Gearing, 1994). 
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1.3.3.2 Receptors 
There are two main members of the IL -1 receptor family, ILA RI and IL-1R11 both of which 
are encoded by a common receptor gene (Sims et al., 1995). Both receptors have a single 
transmembrane domain, but whereas the IL -1RI has a long cytosolic domain (213 amino 
acids) (Sims et al., 1988) the cytosolic domain of the IL -1RII is relatively short (29 amino 
acids) (McMahan et al., 1991). It is not surprising then, that this receptor doesn't transduce 
any cell -signalling pathways (Sims et al., 1993). 
IL -1RI is constitutively expressed in low numbers on nearly all cell types, however the 
number of cell surface receptors increases rapidly on exposure to a number of inflammatory 
mediators including; IFNy, IL -1, IL -2, IL -4, PGE2, PDGF, phorbol esters and promoters of 
inflammation, e.g. LPS (Akahoshi et al., 1988; Koch et al., 1992). IL -1RII is found primarily 
on the surface of neutrophils, monocytes and B- lymphocytes (McMahan et al., 1991) and like 
the IL -1 RI the number of receptors present is also increased during inflammation by a variety 
of mediators including; corticosteroids, IL -1, PGE2 and IL -4 (Re et al., 1994; Colotta et al., 
1995; Colotta et al., 1993). 
IL -1RII can be shed from the cell surface and is often found as a soluble receptor in the 
circulation (Symons et al., 1990). There is increasing evidence that this receptor acts as a 
"decoy receptor ": it binds preferentially and irreversibly to IL -1ß, thus mopping up excess IL- 
0 produced in inflammation, controlling the biological actions of IL -lI (Colotta et al., 
1994). This would seem to be a powerful modulatory role, as normal levels of the soluble 
receptor are approximately 100 pmoles, whereas even following infection IL -11 levels only 
rise to 25 pmoles (Dinarello et al., 1994). 
1.3.3.3 Second messengers 
The levels of IL -1 required to produce its biological action are very low; concentrations in the 
low picomolar range produce effects. Indeed, it seems that only 2 to 3% of Il -1RI need to be 
occupied for a biological action to occur. This suggests that IL -1 receptor signal transduction 
and amplification are highly efficient. However, the exact mechanism underlying this is still 
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not fully understood and some aspects of signal transduction following receptor binding 
remain unclear (O'Neill, 1995). It would seem that IL -1 triggers a diverse range of second 
messengers, receptor activation increases levels of cAMP via a G- protein (Chedid et al., 1989; 
O'Neill et al., 1997). The mechanism by which the receptor couples to the G- protein is 
unconventional as the receptor doesn't have the usual seven transmembrane domains typically 
observed in G- protein coupled receptors (Dohlman et al., 1987). Receptor activation also 
induces a hydrolysis of phospholipids by non -phosphatidylinositol phospholipase C (Rosoff et 
al., 1988; Kester et al., 1989), release of ceramide from sphingomyelin (Mathias et al., 1993) 
and release of arachidonic acid following activation of phospholipase A2 (Gronich et al., 
1994). 
Phosphorylation of proteins follows receptor activation, and is usually accomplished by 
protein kinases (PK). IL -1 is not different in this respect except it activates a whole range of 
PK's including PKC and PKA (Munoz et al., 1990; Mizel, 1990). In addition IL -1 also 
activates mitogen- activated protein (MAP) kinase (Guy et al., 1991). Indeed, it now seems 
that IL -1 initiates a protein kinase cascade involving MAP kinase and kinases, which may be 
the manner in which the IL -1 signal is amplified and it's biological actions seemingly much 
greater than receptor occupancy (O'Neill et al., 1995). 
1.3.3.4 Inhibitory modulation 
Modulation or inhibition of the effects of IL -113 can be accomplished in a number of ways, 
ranging from reducing the amount of IL -13 released, antagonism of IL -1 at a receptor level to 
modulation of its actions by anti -inflammatory cytokines. Inhibition of the enzyme 
responsible for cleavage of pro - EL-1I3 to it's active form would reduce levels of IL-113 
released from cells and thus levels of 1L-1f3 in the circulation. Mice deficient of ICE have 
been shown to be unable to produce the mature form of IL -1(3 (Li et al., 1995). This finding 
led to the study and development of specific inhibitors of ICE. Several inhibitors of ICE have 
been found and their effectiveness at reducing levels of IL -113 has been studied. 
An endogenously released inhibitor of IL -1 activity was detected in the serum of humans 
injected with LPS (Dinarello et al., 1981) and in the urine of patients with monocytic 
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leukaemia (Seckinger and Dayer, 1987). The latter of these has been the most studied and 
characterised as an IL -1 inhibitor and has been termed IL -1 receptor antagonist (IL -lra) 
(Seckinger et al., 1990). IL -lra is more closely related to IL -113 (26% homology) than IL -la 
(18% homology) and all have a similar three- dimensional structure (Vigers et al., 1994; 
Priestle et al., 1989; Graves et al., 1990). It is therefore not surprising that they all bind to the 
same receptor, however, IL- lra lacks a specific binding site for the accessory protein, 
rendering it able to bind to the receptor but unable to transduce a signal (Evans & Robbins, 
1994). Thus, IL -lra competes with IL -1ß for it's receptor and acts as a competitive 
antagonist. IL -1 ra reduces the severity of a number of inflammatory diseases including 
haemodynamic shock induced by LPS in rabbits (Fischer et al., 1992a); adjuvant- induced 
arthritis in rats (Schwab et al., 1991); inflammatory bowel disease in rabbits (Cominelli et al., 
1990) and neutrophil accumulation in inflammatory peritonitis (McIntyre et al., 1991). Levels 
of IL -lra have been observed to increase in inflammatory diseases in experimental animals 
and humans (Fischer et al., 1992b) and therefore may act to regulate and control the biological 
effects of IL -1. A tripeptide antagonist (Lys -D- Pro -Thr) has also been developed which 
selectively acts on the IL -1 receptor and has been used to regulate the biological effects of IL- 
1 (Ferreira et al., 1988). 
Although cytokines are mainly thought of as pro -inflammatory molecules, there are several 
which have been found to have anti -inflammatory properties (Burger & Dayer, 1995) and are 
involved in regulating or modulating the biological actions of inflammatory cytokines in 
particular IL -113. There are three such cytokines; IL -4, IL -10 and IL -13. The manner in which 
these modulate the effects of IL -113 is multifarious. 
IL -4, originally identified as a B -cell growth factor, is mainly produced by TH2 cells (MacNeil 
et al., 1990) and was subsequently found to be involved in proliferation, differentiation and 
activation of various cell types. However, it was also found to have the ability to suppress 
many of the pro -inflammatory effects of monocytes; IL -4 downregulates the production of IL- 
1 by monocytes (Essner et al., 1989; te Velde et al., 1990). In addition IL -4 upregulates the 
production of IL -lra (Vannier et al., 1992) and increases IL -1R11, the `the decoy receptor', 
(Colotta et al., 1993) thus further reducing the biological actions of IL -1. 
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IL -10, like IL -4, is produced by TH2 cells (MacNeil et al., 1990) but, also by monocytes 
activated by other cell types (Spits et al., 1992) including monocytes activated by LPS (de 
Waal Malefyt et al., 1991). The regulation of IL -1's biological actions by IL -10 are somewhat 
similar to those of IL -4; including downregulation of IL -1 production and upregulation of IL- 
ira production (Jenkins et al., 1994). 
IL -13 is also secreted by activated T cells and mast cells (Burd et al., 1995) and acts on a 
receptor which bears similarities to the receptor for IL -4 (Vita et al., 1995; Smerz -Bertling & 
Duschl, 1995). It is not surprising, then, that IL -13 has similar regulatory actions to IL -4. IL- 
13 inhibits the production of inflammatory cytokines, including IL -113, by monocytes activated 
by LPS (Minty et al., 1993). IL -13 also increases expression and release of IL -lra ( Vannier 
et al., 1996) and IL -1RII from monocytes and neutrophils (Colotta et al., 1996; Girard et al., 
1996), thus further regulating the biological activity of IL -1. 
1.3.3.5 Role in inflammatory pain 
Due to its multifunctional actions IL -113 is one of the primary inflammatory mediators. A 
plethora of stimuli are known to induce IL -1 production including LPS, immune complexes, 
activators of macrophages, inflammatory mediators (including TNF) (Epstein & Ramila, 
1986; Billingham, 1987). Levels of IL -1 have been shown to be increased in inflammatory 
diseases. 
The role of IL -1 in nociception has been extensively studied. Local injection of IL -113 has 
been shown to induce both mechanical (Ferreira et al., 1988; Watkins et al., 1994; Davis & 
Perkins, 1994) and thermal hyperalgesia (Perkins & Kelly, 1994). The hyperalgesia was 
interesting, in that local injection could induce a contralateral hyperalgesia, suggesting a 
systemic sensitisation of nociceptors at a site distal to the injection site (Ferreira et al., 1988; 
Perkins & Kelly, 1994). These hyperalgesic actions can be antagonised by IL-lra and the 
tripeptide, Lys -D- Pro -Thr, indicating that these effect are mediated via interaction with the IL- 
1 receptor (Ferreira et al., 1988; Davis & Perkins, 1994). Whether these actions are mediated 
through interaction with IL -1 receptors located on sensory nerves is still unclear. IL-1E3 acts 
on rat dorsal root ganglion cells to produce an immediate increase in Ca ++ suggesting that it 
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can act directly on sensory nerves (Kawatani & Birder, 1992). 1L-lß has also been shown to 
increase spontaneous neural discharge when injected into the paw and also sensitises noxious 
cold- and heat -induced firing of sensory nerves (Fukuoka et al., 1994). However, this 
increase in discharge is not instantaneous suggesting that it may not be due to direct activation 
of sensory nerves. It seems more likely that the effects of IL -113 on sensory nerves is due to 
the release of other mediators which then act on the sensory nerves. IL -1 can induce 
prostaglandin release from a variety of cells, including macrophages, endothelial cells, 
fibroblasts and synovial cells (Billingham, 1987) and also upregulates the inducible 
cyclooxygenase enzyme (COX -2) in human synovial cells (Bathon et al., 1994). However the 
role of prostaglandins in mediating IL -113- induced hyperalgesia is not fully clear. 
Indomethacin has been shown to block the hyperalgesic effects of IL -i(3 in some studies 
(Cunha et al., 1992; Davis & Perkins, 1994), but in others studies a prostaglandin- independent 
is evident (Follenfant et al., 1989). Other possible candidates for mediating this hyperalgesia 
are kinins. IL -1(3 upregulates B1 and B2 receptors and enhances responses to kinins (Galizzi et 
al., 1994; Lerner & Modeer, 1991). Indeed, the hyperalgesia produced can be blocked by 
kinin B1 and B2 antagonists (Davis & Perkins, 1994). Thus, IL -113- induced hyperalgesia may 
be due to the release of other mediators which can act directly on sensory nerves. 
This thesis studied the hypothesis that kinin B i and B2 receptors are involved in mediating the 
hyperalgesia associated with inflammation and investigated the involvement of other 
inflammatory mediators (including, IL-1(3, IL -4, IL -10, prostanoids and nitric oxide) in the 
modulation of kinin- mediated nociception. 
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2. MATERIALS AND METHODS. 
2.1 Electrophysiological studies. 
All experimental animals were housed in an animal house in cages (up to 5 per cage). Rooms 
(12h light/dark) were maintained at 20 °C and had food and water ad libitum. All 
experiments complied with Home Office regulations under project licence (PPL 60/1860) and 
personal licence (PIL 70/10043). 
2.1.1 Induction of arthritis. 
Male Wistar rats (250 -300 g) were injected subdermally with 0.1m1 of Freund's complete 
adjuvant (1.0 mgml -' heat killed Myobacterium tuberculosis in paraffin oil, Sigma) at two 
sites around the ankle joint under temporary anaesthesia induced by halothane (2% in 
oxygen). Experiments were performed on animals after at least 14 days during which time a 
localised swelling, redness and hyperalgesia of the injected ankle had developed and was 
maintained. The circumference of both ankles was measured using a tape measure. For knee 
joint experiments 0.1 ml of Freund's complete adjuvant was injected intra- articularly into the 
knee joint under halothane anaesthesia. The diameter of both knee joints was measured using 
calipers at the time of electrophysiological experiments. 
2.2 Electrophysiological recordings. 
2.2.1 Surgical procedures. 
Male Wistar rats, weighing between 300 and 500 g were anaesthetised with urethane (ethyl 
carbamate 25% w /v, 0.6 m1100g 1 body weight. i.p.). Body temperature was monitored and 
maintained at 37 ± 0.5 °C by a heating blanket connected to a thermistor probe inserted in the 
rectum. A midline incision was made in the ventral aspect of the neck, the trachea was 
cannulated and mean arterial blood pressure was monitored via a cannulated carotid artery. A 
further cannula was inserted into the right femoral artery and advanced until the tip was at the 
level of iliac bifurcation; this cannula was used for the close -arterial injection of drugs to the 
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left hind limb(intra- arterially: i.a.). Drugs were administered in a volume of 0.1 ml and 
washed in with 0.2 ml saline (0.9% w/v aqueous NaC1). 
To record neural discharge from articular afferents innervating the ankle joint, the tibial nerve 
of the left hind limb was exposed by making a medial incision in the skin and then removing 
the muscles overlying the nerve. The primary articular- cutaneous ramus was identified where 
it left the medial plantar nerve (Guilbaud et al, 1985). This dissection provided sufficient skin 
flap to form a liquid paraffin pool (37 °C) covering the exposed nerve and ruptured of the 
cutaneous branches of the PACR. Neural recordings were thus restricted to activity 
originating in the joint capsule and surrounding tissues. 
To record neural discharge from articular afferents innervating the knee joint, the saphenous 
nerve of the left hind limb was exposed by making a making a medial incision in the skin. A 
medial articular nerve was identified where it branched from the saphenous nerve and 
dissected from the muscle and connective tissue. Again, the dissection provided sufficient 
skin flap to form a liquid paraffin pool covering the exposed nerve and the cutaneous branches 
of the medial articular nerve were ruptured. Neural recordings were thus restricted to activity 















Schematic diagram of the dissection and location of the medial articular nerve innervating 
the rat knee joint. 
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2.2.2 Recording afferent neural activity. 
Electrical activity of the PACR or MAN was recorded from fine nerve filaments and in both 
cases the nerve was cut centrally to abolish efferent nerve activity. Fluid (lymph), which 
accumulated close to the nerve, was removed by suction using a syringe connected to a fine 
nylon catheter to prevent short circuits. Electrical activity was recorded extracellularly using 
bipolar platinum- iridium electrodes. The electrical signal was amplified (Neurolog) and 
displayed on a storage oscilloscope (Tektronix 5113). The signal was then digitised using a 
digital audio processor (Sony PCM 701 -ES) for storage on videotape (videotape recorder: 
Sony Betamax SL -HF100 UB). The output from the amplifier was passed through a voltage 
discriminator (Digitimer D130) so that action potentials of a selected amplitude could be 
















Schematic diagram showing the arrangement used for electrophysiological recording, 
collection and storage of data, and electrical stimulation of the nerve at the receptive field. 
High threshold mechanonociceptors with receptive fields in the capsular tissue of either the 
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ankle or knee joint were identified by their activation in response to an intense mechanical 
stimulation with a smooth tipped plastic probe (0.5 -1.0 mm diameter). A probe, consisting of 
a silver wire isolated from a metal cylinder casing was used to estimate the conduction 
velocity of the nerve. This bipolar arrangement gave a localised electrical stimulus of 1 ms 
pulse duration at 1 Hz; voltage was slowly increased (0.1 - 5 V) until spike activation 
occurred. Conduction velocity (v) was calculated by measuring the distance (d) between the 
stimulating electrode and recording electrodes and measuring the time (t) for the action 
potential to travel this distance (v = d / t, ms -1). The distance measured between the 
stimulating and recording electrodes is an estimation of the length of nerve that the action 
potential travels along and assumes the nerve is relatively straight. The conduction velocity 
was therefore an estimate, but the identification of nociceptive fibres was always confirmed by 
testing the unit's sensitivity to capsaicin. Fibres were rejected which were not activated by 
intense mechanical stimulus or capsaicin. Successful recordings were achieved in 
approximately 60 - 70% of all experiments. 
2.2.3 Data Analysis 
The output of the video recorder containing the neural recording was amplified, filtered (band 
pass 10 - 1000 Hz) and fed to a spike processor which counted action potentials of a selected 
amplitude. Each action potential that fell within the window generated a pulse of 1 ms 
duration; the number of impulses occurring in a 0.1s interval was collected and stored on a 
computer programmed to collect over a period of over 600s (software written and supplied by 
Dr. M. Dutia, Dept. of Physiology, University of Edinburgh). Subsequently the data collected 
on disk was analysed on the computer using the same software. 
A computer -generated plot of the neural discharge frequency as a function of time was 
displayed on the computer. From this bar graph neural discharge was analysed in defined 
intervals (pre- injection) and during defined intervals following injection of the drug. Drug 
effects were analysed in one of two ways: 
A: the peak increase in neural discharge (measured over a 5 or 15s period) above the 
neural discharge in the pre- injection control period (measured over a 30s period). 
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B: the total number of impulses generated within the duration of action of the drug 
above the total number generated within the pre- injection control period (30s). 
For example: 
A (increase in discharge) = impulses (response period) - [impulses (control period,30s) 
* (duration of drug action /30)] 
Analysis A only takes into account the maximum magnitude of the response whereas analysis 
B takes into account the duration of action of the drug. 
2.2.4 Statistical analysis 
Statistical analysis of differences between means was carried out using the non -parametric 
statistical tests. The Mann -Whitney U test and Wilcoxan matched pairs test were employed 
where appropriate, and the Null hypothesis rejected at P < 0.05 (two -tailed). 
2.3 Behavioural studies 
In all experiments male Wistar rats were used (90 - 100 g kept at 21 ± 2 °C , 12 h light / dark, 
food and water ad libitum). All experiments complied with Home Office regulations under 
project license (PPL 70/02111) and personal license (PIL 70/10043) 
2.3.1 Mechanical hyperalgesia 
The assessment of mechanical hyperalgesia involved the injection (100 µl, needle: 26 gauge, 
3/8 inch) of inflammatory or hyperalgesic agents into the right knee joint under light 
anaesthesia (enflurane). Both hind paws were placed on separate balanced force transducers, 
amplified (Harvard transducer amplifiers 50- 7996), digitised (CED 101plus) and the data 
collected on computer. A downward force was applied such that the non -injected knee 
tolerated 100 g, which could be visualised on the computer monitor. When this occurred the 
load tolerated by the injected leg was captured on computer (software written by T. Mulcahy, 
SIN/1R, London). Three control readings were taken before intra- articular injection of drugs. 








Diagram showing the apparatus used for assessing the mechanical hyperalgesia resulting 
from intra- articular injection into the right knee joint of the rat. 
Bottom panel shows a screen capture from an experiment. The peaks at the rear show the 
load tolerated by the uninjected knee, the peaks in the foreground show the load tolerated by 
the injected knee. 
2.3.2 Thermal hyperalgesia 
The method for assessment of thermal hyperalgesia involved the injection of inflammatory or 
hyperalgesic agents into the plantar region of the left hind paw. Animals were the placed in 
separate compartments in a glass floored perspex box and allowed to acclimatise (10 -20 min). 
The heat source was positioned manually directly beneath the paw. A ramp heat stimulus was 
applied, using a focused radiant heat beam, to the plantar surface of the paw and the latency to 
paw withdrawal measured (Ugo Basile, Plantar Test, (Hargreaves et al., 1988)). The hind 
paws were exposed to the radiant heat stimulus in a random manner so that no rat had both 
paws exposed immediately after each other. When the rat withdrew its paw, the sudden drop 
of reflected radiation switched off the heat source and stopped the time counter. Two control 
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readings were recorded prior to intraplantar injection of agents (100 µl, needle: 26 gauge, 5/8 
inch). A time course of the effects of drugs and vehicle controls was then carried out at 
various time points (0.5, 1, 2, 3 and 5h post- injection). 
radiant heat source 
Figure 2.4 
Diagram showing the apparatus used for assessing the thermal hyperalgesia resulting from 
intraplantar injection into the left hind paw of the rat. 
Figure shows radiant heat source directed at the plantar surface of the rat paw and the 
automatic timer which will recorded the latency when the paw was withdrawn. 
2.3.3 Data analysis 
In mechanical hyperalgesia experiments, when the load tolerated by the non -injected knee 
reached 100 g the load tolerated by the injected knee was captured by a computer. The load 
tolerated by the injected knee following drug administration was expressed as a percentage of 
the mean of the three pre- injection control measurements. Similarly thermal hyperalgesia data 
following intra- plantar injection was expressed as a percentage of the pre- injection control 
withdrawal latency. 
(post- injection reading /mean control readings)* 100 
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2.3.4 Statistical Analysis 
In both behavioural tests the drug effects were compared to the pre- injection control readings 
using ANOVA followed by Honest Tukey's post -hoc test and the Null hypothesis rejected 
when P < 0.05. 
2.4 Drugs 
All drugs and source of drugs used in this thesis are listed below with the relevant solvents. 
DRUG SOURCE molecular 
weight 
SOLVENT 
bradykinin synthesised in 
house /Sigma 
1261.7 / 1060.2 saline 
capsaicin synthesised in house 308 DMSO 
D- Arginine Sigma 210.7 saline 
D -NAME Sigma 269.7 saline 
desArg9- bradykinin synthesised in 
house /Sigma 
1039.2 / 904.0 saline 
desArg9leu8- bradykinin synthesised in 
house /Sigma 
956.1 / 870.0 saline 
Freund's complete adjuvant Sigma lmgml -I - 
icatibant synthesised in house 1694.3 saline 
indomethacin Sigma 357.8 2 %NaHCO3 
interleukin -10 R &D Systems saline 
interleukin -113 NIBSC saline 
interleukin -4 R &D Systems saline 
intreleukin -1 ra NIBSC saline 
L- Arginine Sigma 210.7 saline 
L -NAME Sigma 269.7 saline 
Urethane (ethylcarbamate) Sigma 89.09 saline 
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3. THE ROLE OF NITRIC OXIDE IN THE MODULATION OF NEURAL 
DISCHARGE AND BK- INDUCED INCREASE IN C- FIBRES INNERVATING 
NORMAL AND ARTHRITIC RAT ANKLE JOINT. 
3.1 Introduction. 
Nitric oxide (NO) is a mediator which can be released from both neuronal and non -neuronal 
cells and may act as a messenger in both the central and peripheral nervous systems (Bredt et 
al., 1990). Nitric oxide synthase (NOS) catalyses the hydroxylation/oxidation reaction which 
converts L- Arginine to citrulline and NO. There are three types of NOS a constitutive 
enzyme, an inducible enzyme, which can be induced by inflammatory mediators, and a 
neuronal form. Nitric oxide interacts with the haem group of soluble guanylate cyclase to 
increase levels of guanosine 3' :5- cyclic monophosphate (cyclic GMP) [see Moncada et al., 
1991 for review] and can directly activate calcium -dependent potassium channels (Bolotina et 
al., 1994). 
A modulatory role for the L- Arginine -NO- cyclic GMP pathway in peripheral and central 
nociceptive processing has been suggested. In the periphery, the NO -cGMP pathway has been 
shown to be involved in both hyperalgesia and antinociception. For example, in the formalin 
model in the rat, spinal neural activity is reduced by concomitant administration (with 
formalin) of L -NAME, a NOS inhibitor, into the receptive field (Haley et al., 1992). However 
topical administration of nitroglycerin, which can raise levels of NO is antinociceptive in the 
Randall -Selitto paw pressure test (Ferreira et al, 1991). In addition, L- Arginine, a NO 
precursor, is antinociceptive in carageenan- induced mechanical hyperalgesia (Duarte et al., 
1992) and, depending on the dose used, has been reported to be both hyperalgesic (0.1 - 1µg, 
intraplantar) and antinociceptive (10 [tg, intraplantar) in the formalin- induced paw licking 
model of hyperalgesia (Kawabata et al., 1993). 
Bradykinin has excitatory and sensitising actions on sensory nerves (Dray et al., 1988; Rang et 
al., 1991), and produces pain when applied to the human nasal mucosa, or to a blister base 
(Whalley et al., 1987). Kinin levels have been shown to be elevated in synovial fluids from 
patients with inflammatory conditions such as rheumatoid arthritis (Jasani et al., 1969) and 
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this raises the possibility that bradykinin plays a role in the hyperalgesia associated with these 
conditions. Bradykinin also causes release of nitric oxide from vascular endothelial cells 
(Bogle et al., 1991), and a role for the NO -cGMP pathway in the desensitisation of bradykinin 
receptors has been suggested. Sodium nitroprusside, a NO donor, increased bradykinin 
desensitisation whereas NOS inhibitors reduced desensitisation in cultured sensory neurons 
(McGehee et al., 1992), and responses of peripheral sensory nerves to bradykinin have been 
shown to be reduced by sodium nitroprusside and dibutyrl -cGMP (Dray et al., 1992). 
We have investigated the effects of a NOS inhibitor, L -NAME, and the NO precursor, L- 
Arginine, on the spontaneous neural discharge of articular high threshold mechanonociceptors 
recorded from normal and chronically inflamed (adjuvant -arthritic) ankle joints in rats 
anaesthetised with urethane. We have also determined whether responsiveness of the joint 
mechanononociceptors to bradykinin was affected by modulating the level of endogenous NO 
by using L -NAME and L- Arginine. 
3.2 Methods. 
As described in section 2.3. 
3.3 Results. 
Afferent units from fifteen normal and seventeen arthritic rat ankle joints were studied. For 
electophysiological experiments arthritic rats were used between 14 and 33 days (average 20 ± 
1 days) after injection of adjuvant when the left ankle had swollen by 38 ± 2% (range: 21 - 
48%) compared to the contralateral joint. All the units examined were excited by capsaicin (1 
- 10 µg, i.a.) and the mean afferent conduction velocity was 0.67 ± 0.01 ms -' (n = 17; range: 
0.16 - 1.5 ms -1) from normal and 0.64 ± 0.07 ms-1 (n = 17; range: 0.2 - 1.6 ms -1) from arthritic 
ankle joints, i.e. within the range for C -fibre afferents (< 2.5 ms-I). 
Effects of L -NAME on the neural discharge of C- fibres. 
L -NAME (10 - 20 mg.kg, i.a.), but not D -NAME (30 mgkg', i.a.), increased neural discharge 
of C -fibre mechanonociceptor afferents (see Figure 3.1) in 82% (14/17 units from 9 
experiments) of units from normal ankle joints and 82% (14/17 units from 8 experiments) of 
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30 mgkg 1 
L -NG nitroArginine methyl ester (L -NAME) but, not its inactive isomer D -NG 
nitroArginine methyl ester (D -NAME) increases neural discharge from articular 
nociceptors. 
Bargraphs illustrate the increase in discharge evoked by L -NAME (20 mgkg -1, i.a. at arrow) 
[A] but not its inactive isomer D -NAME (30 mgkg 1, i.a. at arrow)[B]. The inset illustrates 
20 fast oscilloscope sweeps of the activated unit. 
There was no difference in the increase evoked by L -NAME in afferents from normal or 
arthritic ankle joints, but in both cases it was significantly greater than that evoked by the 

















-o- NORMAL (n =3 - 6) -- ARTHRITIC (n =3 - 5) 
1 10 100 
DOSE (mg kg-l) 
L -NAME increases neural discharge of articular nociceptors in normal and arthritic rat 
ankle joints. 
The mean peak increase (15 s period) above the pre- injection control level produced by L- 
NAME (1 - 20 mgkg -1, i.a) is shown. The increase in discharge produced by L -NAME (10 & 
20 mgkg-1) in both normal and arthritic ankle joints was statistically significant when 
compared with the inactive isomer D -NAME (* p < 0.05, Mann Whitney U test). Vertical 
lines represent standard error of the mean. 
The increase in neural discharge evoked by L -NAME was typified by long delay to onset (92 
± 20 s, normal joints; 130 ± 41 s, arthritic joints) and long duration (187 ± 38 s, normal joints; 
249 ± 101 s, arthritic joints) of action, there was no statistical significance between normal 
and srthritic ankle joints. This duration of action was considerably shorter than the duration of 
the increase in blood pressure observed with L -NAME, greater than 30 minutes, suggesting 
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D -NAME 30 mgkg' 4 0.9 ± 0.3 1.0 ± 0.2 - - - 
SALINE 6 1.4 ± 0.5 2.4 ± 0.4 - - - 
L -NAME 1 mgkg' 3 1.1 ± 0.1 0.8 ± 0.2 - - 153 235 30 
L -NAME 10 mgkg' 6 1.2 ± 0.3 3.1 ± 0.4 68 ± 23 148 ± 23 110 ± 18 170 ± 20 31 
L -NAME 20 mgkg' 6 1.1 ± 0.3 3.6 ± 0.5 92 ± 20 187 ± 38 123 ± 14 180 ±26 38 
ARTHRITIC 
D -NAME 30 mgkg' 3 0.5 ± 0.2 0.7 ± 0.1 - - - 
SALINE 5 1.8 ± 0.5 2.2 ± 0.5 - - - 
L -NAME 1 mgkg' 3 1.5 ± 0.2 1.8 ± 0.6 - - 133 233 30 
L -NAME 10 mgkg' 4 2.0 ± 0.4 4.2 ± 0.6 59 ± 15 123 ± 14 127 ± 11 187 ± 21 32 
L -NAME 20 mgkg' 5 1.1 ± 0.3 4.6 ± 0.7 130 ± 41 249 ± 101 133 ± 13 229 ± 28 45 
Table3.1: Summary effects of L -NAME on ankle joint C-fibre mechanonociceptors 
All values are mean ± s.e.mean, where possible. In some cases due to technical difficulties, 
blood pressure recording were not possible. 
Neither the NO precursor, L- Arginine (10 - 50 mgkg', i.a.) nor the inactive isomer D- 
Arginine (50 mgkg', i.a.) had any effect on the basal discharge of nociceptive afferents 
recorded from either normal or arthritic ankle joints; L- Arginine, however, was biologically 











D- ARGININE 50 mgkg' 3 0.7 ± 0.24 1.1 ± 0.36 - - 
SALINE 5 1.4 ± 0.48 2.4 ± 0.39 - - 
L- ARGININE 10 mgkg"' 3 0.9± 0.76 1.3 ±0.18 108±35 94 ±32 
20 mgkg' 4 0.7 ± 0.09 0.9 ± 0.31 96 ± 4 88 ± 4 
50 mgkg' 2 0.4 ± 0.15 0.8 ± 0.1 
ARTHRITIC 
D- ARGININE 50 mgkg' 5 1.3 ± 0.34 1.8 ± 0.42 - - 
SALINE 5 1.8 ±0.50 2.2 ±0.50 - - 
L- ARGININE 10 mgkg' 5 1.6 ±0.46 2.2 ±0.53 100 ±8 88± 11 
20 mgkg' 4 1.9 ±0.57 1.8 ±0.55 94 ±2 80 ±5 
50 mgkg' 2 1.1 ± 0.79 0.9 ± 0.21 92 88 
Table 2: Summary effects of L- Arginine on ankle joint C-fibre mechanonociceptors 
All values are mean ± s.e.mean, where possible. In some cases due to technical difficulties, 
blood pressure recording were not possible. 
However, co- administration of the NO precursor, L- Arginine (50 mgkg', i.a.), did attenuate 
the increase in neural discharge evoked by L -NAME (20 mgkg', i.a.) in both normal and in 




® + L-Arg 50mgkg-1 
NORMAL ARTHRITIC 
L- Arginine reduces L- NAME -induced increase in neural discharge in articular nociceptors 
recorded from normal and arthritic rat ankle joints. 
Each column shows the mean peak increase (15s period) in discharge above the pre - injection 
control level evoked by L -NAME (20 mgkg 1, i.a) before and after co- administation of L- 
Arginine (50 mgkg', i.a) in normal (n = 6) and arthritic (n = 5) rats. The increase in 
discharge produced by L -NAME was significantly reduced by L- Arginine in normal and in 
arthritic rat ankle joints (* p < 0.05, Wilcoxan matched pairs test). Vertical lines above bars 
represent the standard error of the mean. 
Effects of L -NAME and L- Arginine on bradykinin- induced activation of articular C -fibre 
afferents. 
Bradykinin (10 µg i.a.) was injected before and 10 minutes after L -NAME (20 mgkg -I, i.a.) 
when the baseline neural discharge had returned to pre- injection control levels. At this point 
the blood pressure remained elevated - indicating that NOS was still inhibited. Close intra- 
arterial injection of L -NAME (20 mgkg 1) increased the responses of nociceptors to 
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Bk 10µg ® + L-NAME 20mgkg-1 
ARTHRITIC 
i 
L -NAME enhances bradykinin- induced excitation of articular nociceptors in arthritic 
ankle joints, but not normal joints. 
Each bar represents the mean peak increase (15s period) in nociceptor discharge above the 
pre - injection control level following injection of bradykinin (10µg, i.a.) before and 10 minutes 
following injection of L -NAME (20 mgkg 1, i.a.) in normal (n =3) and arthritic (n =3) rat ankle 
joints. The bradykinin - induced excitation was significantly increased following L -NAME in 
afferents from arthritic ankle joints (* p < 0.05, Wilcoxan matched pairs test). The basal 
discharge before both injections of bradykinin was not significantly different (0.9 00.3 & 1.3 
±0.3 i.p.s in normal joints; 1.7 ±0.5 & 2.2 ±0.5 i.p.s in arthritic joints). Vertical lines above 
the bars represent the standard error of the mean. 
Conversely, bradykinin- induced (30 .tg i.a.) activation of articular nociceptive afferents was 
reduced by co- administration of L- Arginine (50 mgkg 1, i.a.), in both normal and arthritic 
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ankle joints. The initial response to bradykinin could be recovered within 10 minutes (Figure 
3.5). The inactive isomers D -NAME and D- Arginine had no effect on bradykinin- induced 
activation of nociceptive afferents. 
Figure 3.5 
7 
NORMAL (n =3) 
ARTHRITIC (n =3) 
Bk 30µg Bk 30µg 
(L-Arg 50mg/kg) 
Bk 30µg 
L- Arginine reduces bradykinin- induced excitation of articular nociceptors in normal and 
arthritic ankle joints. 
Each bar represents the mean peak increase (15s period) in discharge above a pre - injection 
control level produced by bradykinin (30µg, i.a.) 10 minutes before, after co- administration 
of L- Arginine (50 mgkg -1, i.a.) and recovery 10 minutes after L- Arginine in normal and 
arthritic rat ankle joints. The bradykinin- induced excitation was significantly reduced after L- 
Arginine (* p < 0.05, Wicoxan matched pairs test). Vertical lines above bars represent the 
standard error of the mean. 
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3.4 Discussion. 
These results provide evidence that endogenous NO may have anti -nociceptive actions in the 
periphery. The data demonstrates that L -NAME, a NOS inhibitor, but not its inactive isomer, 
D -NAME, increased nociceptive discharge from joint mechanonociceptors in both normal and 
arthritic rat ankle joints. The increase in nociceptive discharge evoked by L -NAME was 
reduced by concomitant administration of the NO precursor, L- Arginine. Furthermore, the 
increase in bradykinin- evoked excitation of C -fibre afferents in arthritic rat ankle joints by L- 
NAME and reduction of this effect by L- Arginine in normal and arthritic conditions suggests 
a role for NO in modulating the responsiveness of nociceptors to bradykinin in both of these 
states. 
L -NAME competes with L- Arginine for the active site of NOS and thus blocks the conversion 
of L- Arginine to NO (Moncada et al., 1991). The increase in nociceptor discharge seen 
following the inhibition of NOS could, therefore, be due to removal of a tonic inhibitory (anti - 
nociceptive) action of NO. This would be consistent with the increase in the reduction in 
neural discharge by exogenous L- Arginine. In agreement with the present results, it has been 
shown that intraplantar L- Arginine is antinociceptive in carrageenan- induced hyperalgesia via 
activation of the NO- cyclic GMP (Duarte et al, 1990; Kawabata at al, 1994). In addition 
topical application of nitroglycerin has been shown to reduce prostaglandin E2- induced 
hyperalgesia (Ferreira et al, 1991), and high doses of L- Arginine (intraplantar) are 
antinociceptive in formalin- induced hyperalgesia (Kawabata et al., 1994). L -NAME also 
increases blood pressure which raises the possibility that the effects on nociceptors are 
secondary to vascular effects. However, since other vasoconstrictor agents (e.g. endothelin -1 
and endothelin -3) had no effect on the activity of nociceptors in our preparation (Kelly et al, 
1994), this seems improbable. 
L -NAME increased the bradykinin- induced excitation of C- fibres innervating arthritic, but not 
normal, ankle joints. However, L- Arginine attenuated responses to bradykinin in nociceptive 
afferents from both normal and arthritic ankle joints. This suggests a role for NO in altering 
the responsiveness of nociceptors to bradykinin. A possible mechanism for this effect could 
be modulation of the desensitisation to bradykinin responses in nociceptors. There is support 
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for such a mechanism in the literature : for example, in the neonatal rat tail spinal cord 
preparation bradykinin- induced activation is attenuated by dibutyryl cGMP and a NO donor, 
sodium nitroprusside (Dray et al., 1992). Furthermore, NO activates guanylate cyclase, which 
in turn increases levels of cGMP (McGehee et al., 1992) and activates cGMP. This may 
result in phosphorylation and desensitision the bradykinin receptor or modulation of the 
activity of the receptor -coupled ion channel (Dray et al., 1993). 
Inflammatory mediators such as bradykinin (Bogle et al., 1991), substance P (Hughes et al., 
1990) and cytokines (Pfeilschifter et al., 1992) can release NO. In patients with rheumatoid 
and osteoarthritis the level of NO (measured in the form of nitrite) in the serum and synovial 
fluid is elevated (Farrell et al., 1992). It is possible that levels of NO may be insufficient in 
normal rat ankle joints to reduce the responsiveness of afferents to bradykinin thus explaining 
the lack of effect of L -NAME under these conditions. 
These results suggest of a role for endogenous NO in anti -nociception, acting via tonic 
inhibition of C -fibre nociceptors and possibly involving generation of cGMP. These findings 
are also consistent with a role for the L- Arginine -NO pathway in the desensitisation of 
bradykinin receptors that are on joint mechanonociceptor C- fibres. Increasing the endogenous 
level of NO may, therefore, reduce the activity of nociceptors and limit pain evoked by 
noxious stimuli and algesic mediators in the periphery. 
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4. EFFECTS OF KININS ON NEURAL DISCHARGE FROM C- FIBRES 
INNERVATING THE RAT KNEE JOINT 
4.1 Introduction. 
There are several problems associated with studying neural recordings from the ankle joint. 
The main one of these is the actual anatomy of the joint, the joint is very complex with a lot of 
small bones. This makes it difficult to inject into the joint itself, and indeed it was only 
possible to inject inflammatory agents subdermally around the joint resulting in only a 
superficial inflammation. It was decided that in order to study the effects of individual 
inflammatory mediators on joint nociceptors it would be much more beneficial if injections 
could be made directly into the joint space resulting in a more localised inflammation. 
The rat knee joint is a much simpler joint to work with, with respect to injections into the 
joint, and is very similar in anatomy to the human knee joint (Hildebrand et al., 1991). 
Schaible and his colleagues have investigated in great detail neural recordings from C- fibres 
innervating the cat knee joint. There are two main articular nerves which innervate the cat 
knee joint, the medial articular nerve (MAN) and the posterior articular nerve (PAN), both of 
which contain a high proportion of thin myelinated and unmyelinated fibres (Langford & 
Schmidt, 1983). In normal joints these fibres have small receptive fields and are only 
activated by movements outwith the physiological range or by noxious mechanical stimuli. In 
inflamed joints, however, the receptive field is larger, nerves become sensitised and can be 
activated by normally non -noxious movements or by relatively low mechanical stimulation 
(Schaible & Schmidt, 1983a; Schaible & Schmidt, 1983b; Grigg et al., 1986; Schaible & 
Schmidt, 1985). In addition these nerves can be activated by inflammatory mediators such as 
bradykinin (Kanaka et al., 1985). 
It was decided, therefore, to develop a rat knee joint model for recording from C- fibres. As 
with the cat knee joint there are two main nerves which contain a large majority of thin 
myelinated and unmyelinated fibres that innervate the rat knee joint, a MAN which branches 
from the saphenous nerve and a PAN which branches from the sciatic nerve (Marinozzi et al., 
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1991) and the MAN has been shown to contain a majority of thin myelinated and 
unmyelinated fibres with nerve endings within the knee joint (Hildebrand et al., 1991). 
Records of neural discharge from these articular nerves in the rat has, so far, been limited or 
not attempted. The aim of these studies was, therefore, to develop a rat model for studying the 
effects of inflammatory mediators on neural discharge in C- fibres innervating the knee joint. 
For the purpose of these studies it was decided to record from the MAN as it was easier for 
experimental design and required less invasive surgery. 
4.2 Methods. 
As described in section 2.3. 
4.3 Results. 
The following studies on neural recordings from the rat knee joint were obtained from a total 
of 80 experiments. Approximately 60% of these experiments were successful in that they 
satisfied the following criteria: putative C- fibres innervating the rat knee joint were identified 
initially by manually probing around the knee joint. They were then defined as C- fibres if, the 
conduction velocity was within the C -fibre range (0.64 ± 0.08 ms-1, range 0.1 - 2 ms -1) and 





delay (s) duration (s) 
capsaicin 1-311,g, 1.4 ± 0.3 34.5 ± 4.5 1.9 ± 0.4 11.5 ±1 
i.a. (n=57) (range 0 - 9.7) (range: 3.8 - 102) (range: 0 -7) (range: 4 -23) 
Table 4.1. 
Summary of the effects of capsaicin on neural discharge in knee joint C-fibres. 
All values are mean ±s.e.mean. 
The increase in neural discharge induced by capsaicin had a very short delay to onset and a 
relatively short duration of action (Table 4.1.). There was no significant difference between 
the conduction velocities or the response to capsaicin in normal or inflamed knee joints (FCA- 
or IL -1(3- induced). Injection of saline 0.3 ml, i.a. had no significant effect on neural discharge 




Capsaicin increases neural discharge of knee joint C-fibres. 
Bargraphs illustrate an example of the increase in discharge evoked by capsaicin (3 µg, i.a. 
at broken line) in an untreated knee joint (n = 1), each bar represents 1 s. The inset 
illustrates 20 fast oscilloscope sweeps of the activated unit. 
Recordings were made from arthritic knee joints at least 14 days after injection of FCA when 
the inflammation, as measured by callipers, was 17 ± 1.7 % greater in diameter when 
compared to the contralateral (uninjected) knee joint. 
Effects of bradykinin on the neural discharge of C- fibres in normal and arthritic knee joints. 
Bk (3 - 3014, i.a.) produced a dose dependent increase in neural discharge from C- fibres in 
both normal and arthritic knee joints. Although the peak increase observed in normal knee 
joints had a tendency to be greater than that seen in arthritic knee joints (30 fig, La. produced a 
peak increase of 8.5 ± 2.2 i.p.s. above pre- injection control discharge 2.4 ± 1.2 i.p.s in arthritic 
knee joints compared to 23 ± 10.7 i.p.s. above pre- injection control discharge 3.6 ± 1.7 i.p.s. 
in normal knee joints), this did not reach statistical significance and there was no difference in 
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the total number of impulses above the pre- injection control in both normal and arthritic knee 




























DOSE BK Ng, i.a. 
100 
Bradykinin increases in neural discharge in normal and arthritic knee joints. 
(A) The peak increase in neural discharge induced by Bk, i.a. in normal knee joints and 
arthritic knee joints. (B) The total increase in neural discharge induced by Bk, La. in normal 
and arthritic knee joints. All values are mean ± s.e.m., * p < 0.05 compared to saline, Mann 
Whitney U test. 
The increase in neural discharge induced by Bk was typified by a short duration to onset and a 
relatively long duration of action (Table 4.2.) 
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NORMAL delay to onset (s) duration of action (s) 
3 µg 9 ±6.4 84 ±57 
10µg 2 ±0.8 67 ±38 
30µg 2.8 ±1.5 79 ±116 
ARTHRITIC 
3µg 3.8 ±0.8 36 ±9 
10µg 3.7 ±0.8 71 ±14 
30µg 3.2 ±0.8 91 ±20 
Table 4.2. Summary of delay to onset and duration of action of Bk 
All values are mean ± s.e.mean. 
In both normal and arthritic joints (Figure 4.3) a B2 antagonist icatibant (10 tgkg 1, i.a.) 








pop ¢ 25 a 
W Z 













w á 350 
> E 
m 300 a 0 
0 a, ~ 250 a z 
O 












-O- Bk (n=4) 


























> É 250- 
O ,- 
á ó 200- 
W 2 
¿ z 150- 
w O 
CC O 






-O- Bk (n=4) 
-E-+ icatibant 10µgkg-1 (n=4) 
10 100 
10 
DOSE BK Ng, i.a. 
100 
Bradykinin- induced increase in neural discharge in normal and arthritic knee joints is 
blocked by icatibant. 
(A) Peak increase in neural discharge induced by La. Bk alone and after icatibant, 10 pgkg-l. 
(B) Total increase in neural discharge induced by La. Bk alone and after icatibant, 10,ugkg- 
I,i.a.. Graphs on the left show normal joints and on the left arthritic joints. All values are 
mean ± s. e.m., * p < 0.05 compared to Bk alone, Mann Whitney U test. 
The kinin B1 receptor agonist, desArg9 -Bk increased neural discharge from C- fibres 
innervating arthritic knee, but not normal knee joints. DesArg9 -Bk, 301ig and 100µg, i.a., 
produced a peak increase in neural discharge (1.1 ± 0.07 i.p.s. above pre- injection control 
discharge 0.8 ± 0.2 i.p.s. and 2.1 ± 0.8 i.p.s. above pre- injection control discharge L2 ± 0.3 
i.p.s., respectively) which, although not as pronounced as that produced by Bk, was 
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DOSE desArg9BK (µg) 
100 
DesArg9 -Bk increases neural discharge in arthritic knee joints , but not normal knee joints. 
(A) The peak increase in neural discharge induced by desArg9 -Bk, i.a. in normal and arthritic 
knee joints. (B) The total increase in neural discharge induced by desArg9 -Bk, i.a. in normal 
and arthritic knee joints. All values are mean ± s.e.m., * p < 0.05 compared to normal, Mann 
Whitney U test. 
The increase produced was typified by a longer delay to onset to action and a longer duration 
than that evoked by Bk (Table 4.3.). 
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delay to onset (s) duration of action (s) 
30µg 25 ±9.8 230 ±39 
100µg 70 ±50 166 ±44 
Table 4.3. Summary of delay to onset and duration of action of desArg9 -Bk. 
All values are mean ± s.e.m (n = 4). 
The kinin B1 receptor antagonist, desArg9leu8 -Bk (1 mgkg 1, i.a.), but not the B2 receptor 
antagonist, icatibant (10 µgkg', i.a.), reduced the increase in neural discharge induced by 
desArg9 -Bk when administered 1 minute before the agonist ( Figure 4.5.). 
desArg9-Bk (n=4) 
® + icatibant (10Ngkg-t) 





des Arg9 Bk- induced increase in neural discharge in normal knee joints is blocked by B1 
but not B2 antagonists.. 
(top panel) The peak increase in neural discharge induced by desArg9 -Bk, i.a., with icatibant 
10,ugkg 1, i.a. and desArg9leu8-Bk Imgkg 1, i.a. (lower panel) The total increase in neural 
discharge induced by desArg9 -Bk, i.a. with antagonists as above. All values are mean ± 
s.e.m., * p < 0.05 compared to open bars, Wilcoxan matched pairs test. 
56 
4.4 Discussion. 
These results demonstrate a novel model for recording neural discharge from C- fibres 
innervating the medial side of the rat knee joint. This model proved useful for assessing the 
actions of kinins in both normal and inflamed knee joints. In both normal and arthritic knee 
joints Bk produced an increase in neural discharge which was mediated via kinin B2 receptors. 
On the other hand desArg9 -Bk only produced an increase in neural discharge in inflamed knee 
joints, an action which was mediated via kinin B1 receptors. The antagonism of the responses 
to Bk and desArg9 -Bk by B2 and B1 kinin receptor antagonists, respectively, demonstrate that 
the responses to these agonists were mediated by their respective receptors. 
The increase in neural discharge evoked by bradykinin from C- fibres was comparable to that 
observed previously in the cat knee joint model (Kanaka et al., 1985). The antagonism of Bk 
responses by a kinin B2 antagonist suggests that the activation of C- fibres by Bk was via B2 
receptors and the short delay to onset of action is consistent with a direct action of Bk on the 
C -fibre terminals. This is consistent with the localisation of kinin B2 receptors on sensory 
neurons (Steranka et al., 1988). This increase in neural discharge evoked by Bk can be 
correlated to behavioural hyperalgesia. Bk has been shown to produce pain and hyperalgesia 
in humans (Whalley et al., 1987; Jansen et al., 1990; Manning et al., 1991) and a number of 
animal models including FCA- induced arthritis in the rat (Davis et al., 1994), paw withdrawal 
thresholds in the rat (Khasar et al., 1993) and in carrageenan- induced inflammation in the rat 
paw (Carey et al., 1990). The doses of Bk that were effective in the present studies are 
somewhat higher than those used in behavioural models, but were within the same range as 
those used to activate testicular C- fibres (Mizumura et al., 1990) and in cat knee joint C- fibres 
(Kanaka et al., 1985). 
The observation that kinin B1 agonists only increased neural discharge in inflamed knee joints 
is consistent with the evidence that B1 kinin receptors are rarely, if at all, present under normal 
physiological conditions. In fact, originally B1 mediated effects were only seen in vascular 
smooth muscle preparations in vitro and in these preparations responses to desArg9 -Bk were 
minimal initially, but increased over time (Regoli et al., 1977). Subsequent studies 
demonstrated that this increase in responsiveness to desArg9 -Bk could be mimicked by pro- 
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inflammatory agents including lipopolysaccharide and cytokines (Deblois et al., 1991). More 
recently, kinin B1 receptors have been found to be involved in inflammatory hyperalgesia 
(Perkins et al., 1992). 
Whether the B1 mediated increase in neural discharge is via a direct action on the sensory 
neuron cannot be determined from the present experiments, although the longer delay to onset 
might suggest that the B1 receptors are not localised on the nociceptors. Indeed, Davis et al., 
1996 found no evidence of B1 receptors on dorsal root ganglion cells in rats which have been 
pre- treated with FCA. It is, therefore, more likely that B1 receptors are induced on non - 
neuronal cells or inflammatory cells, activation of these leading to the release mediators which 
then act directly on the nociceptor. 
Kinin B 1 and B2 receptor antagonists have been shown to be antinociceptive in a number of 
inflammatory hyperalgesia models including FCA- induced arthritis in the rat knee (Davis & 
Perkins, 1994A), UV- induced thermal hyperalgesia (Perkins et al., 1993) and the formalin 
model in the rat (Correa & Calixto, 1993). However in the present model, there was no effect 
of either desArg9leu8 -Bk or icatibant on the spontaneous neural discharge. This agrees with 
studies done in the arthritic cat knee joint where neither kinin B1 nor B2 antagonists had any 
effect on the on -going neural discharge (Messlinger et al., 1993). However, in the present 
model this may be difficult to evaluate as the relatively low background discharge 1 - 1.5 i.p.s. 
of individual C- fibres makes it difficult to measure decreases in neural discharge. In order to 
observed such a decrease in neural discharge with kinin antagonists it may be necessary to 
induce C -fibre activity , possibly by studying a mechanical- or movement -induced increase in 
neural discharge. 
The present results demonstrate that this novel model is useful in studying the effects of kinins 
on C- fibres innervating the rat knee joint and relating these effects to behavioural hyperalgesia 
models. In addition these findings provide further evidence that Bk acts via B2 receptors on 
C- fibres to produce hyperalgesia and that in inflammatory conditions kinin B1 receptors can 
be induced which, upon activation by selective B1 agonists results in C -fibre activation. 
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5. THE ROLE OF IL -113 IN HYPERALGESIA AND MODULATION OF EFFECTS 
OF KININS IN HYPERALGESIA ELECTOPHYSIOLOGICAL AND 
BEHAVIOURAL STUDIES. 
5.1 Introduction. 
As previously discussed, cytokines have been shown to induce kinin B 1 receptor- mediated 
actions in vascular smooth muscle and B1 kinin receptor- mediated hyperalgesia in vivo 
(Deblois et al., 1989; Perkins & Kelly, 1994; Davis & Perkins, 1994). A role for cytokines in 
inducing B 1 kinin receptors is consistent with the increased levels of several cytokines that has 
been observed in conditions such as rheumatoid arthritis in man. Cytokines have a multitude 
of pro -inflammatory actions, and very low levels are required to produce a biological action. 
Of particular interest for these studies is IL -113. IL -113 induces B 
1 receptors in vascular smooth 
muscle an action which appears to require de novo synthesis as it is blocked by an inhibitor of 
protein synthesis, cyclohexamide (Deblois et al., 1991). 
Local injection of IL -113 has been shown to reduce withdrawal thresholds in paw pressure test 
(Ferreira et al., 1988) and produce both a thermal and mechanical hyperalgesia, an effect 
involving both kinin B1 and B2 receptors (Perkins & Kelly, 1994; Davis & Perkins, 1994). IL- 
1 13 can also release a variety of inflammatory mediators from inflammatory cells including 
prostanoids and kinins and has been shown to upregulate kinin B 
1 
and B2 receptors on smooth 
muscle cells and fibroblasts and can enhance responses to kinins (Galizzi et al., 1994; Lerner 
& Modeer, 1991). 
The aim of these studies was to investigate the effects of local injection of IL -1ß on 
spontaneous and Bk- evoked neural discharge and also to investigate the role of IL -113 in 
inducing the B1- mediated increase in neural discharge which was observed in arthritic knee 
joints. Behavioural hyperalgesia experiments were also carried out in order to try and correlate 
the in vitro findings to the situation in vivo. 
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5.2 Methods. 
Neuronal experiments were carried out as described in section 2.3. Dose responses of Bk and 
desArg9 -Bk were obtained and then the nerve was then lowered to allow i.art. injection of 
either 1L -1ß, boiled IL -1 or IL -lra. The nerve was then raised and neural discharge was 
subsequently measured for 1 hour after i.art. injection when further dose responses to kinins 
were obtained. The same fibres were observed before and after i.art injection by carefully 
observing the size and shape of the activated spikes by use of an oscilloscope. 
Behavioural experiments were as described in section 2.4. Dose response curves with local 
injections of IL-1[3, Bk and desArg9 -Bk were obtained. To establish the effects of IL -113 on 
kinin activity, concomitant administration of kinins and cytokines together with antagonists, 
when used, were administered locally. 
5.3 Results. 
In the behavioural experiments discussed in this section, the pre- injection control values were 
as follows. The load tolerated before i.art. injection was 94.6 ± 0.7g (range: 71 - 146g, n = 
355). The withdrawal latency in the thermal hyperalgesia model before i.pl. injection was 10 
± 0.2 s (range: 6.7 - 17.1s, n = 136). 
Effects of IL -1/3 on the neural discharge of C- fibres and behavioral hyperalgesia. 
IL -lß (10 - 100 units, i.art.) increased the spontaneous on -going neural discharge in C- fibres 
innervating the rat knee joint (Figure 5.1). The increase in neural discharge had two phases, 
an initial peak 8 to10 minutes after injection when the discharge increased from 0.3 ± 0.1 i.p.s. 
to 1.5 ± 0.2 i.p.s., and a delayed peak 40 minutes after injection where discharge increased 
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IL -l13 increases neural discharge in knee joint C-fibres. 
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IL -113 1 u (top graph, n = 3), 10 u (middle graph, n = 3) and 100 u (bottom graph, n = 9). All 
values are expressed as mean ±s.e.mean. 
Due to the temporal variation between individual experiments, statistical analysis was done on 
the total increase in neural discharge following intra- articular injection. For this analysis the 
assumption was made that the pre- injection control discharge would remain constant 
throughout. This is valid as (inactivated) boiled IL -113 did not induce a significant increase in 
neural discharge (Figure 5.2), whereas, IL -1ß, 100u, i.art., produced a significant increase in 
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IL -lß increases neural discharge in knee joint C-fibres. 
(top graph) Total impulses following boiled IL-1p compared to control and (lower graph) 
IL-1p 100 u. Bar graphs show individual experiments with the corresponding mean ± 
s. e. mean, * p < 0.05 compared control, Wilcoxan matched pairs test. 
The increase in neural discharge produced by IL -lß (100u, i.art.) was blocked by co- injection 
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of IL-lra (0.11.tg, i.art.) [Figure 5.3.]. 
o 
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IL -lß- induced increase in neural discharge is blocked by IL -Ira. 
(top graph) Total impulses following IL-1 fl compared to control and (lower graph) IL -1 ß co- 
injected with IL -1 ra 0.1 ,ug. Bar graphs show individual experiments with the corresponding 
mean ± s.e.mean, * p < 0.05 compared control, Wilcoxan matched pairs test. 
IL -1(3 (0.1 - 10 u, i.art.), but not boiled IL -1(3 (10 u) reduced the load tolerated by the injected 
knee (Figure 5.4.). The decrease in load tolerated had reached significance lh after injection 
when the load tolerated had fallen to 83.7 ± 9.3 % (I u, i.art.) and 75.5 ± 7.3 % (10 u, i.art) of 
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the pre- injection control. The maximum hyperalgesia was 5h after injection when the load 









* -- boiled IL-1 10u (n=16) -- IL-1[3 0.001u (n=15) 
-0- IL-1f3 0.01 u (n=8) 
-A- IL-1[3 0.1u (n=22) 
-y- IL-113 lu (n=15) 
-S- IL-113 10u (n=14) 
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TIME AFTER INJECTION (h) 
Figure 5.4 
IL -1j3 induces a mechanical hyperalgesia in the rat knee joint. 
Load tolerated following i.art. injection of IL -1/3 (0.001 - 10 units) and inactivated IL -113. All 
values are expressed as means ± s.e.mean, *p < 0.05 compared to pre- injection control. 
IL -113 (1 - 10 u,i.art.) but not boiled IL-1I3 also reduced the latency of paw withdrawal to a 
focused radiant heat lamp. This was significant 30 minutes after intra- plantar injection when 
the withdrawal latency had fallen to 66.8 ± 7.1 % (1 u) and 71.6 ± 13.5 % (10 u) of the pre - 
injection control. A maximum reduction in withdrawal latency of 54.2 ± 7.9 % was observed 
1 h after injection (Figure 5.5.). 
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* -- boiled IL-113 10 u (n=6) -- IL-1E3 0.1 u (n=12) 
-A- IL-113 1 u (n=12) 
-y- IL-113 10 u (n=10) 
I ' 1 ' I ' I ' I ' 1 ' I 
-1 0 1 2 3 4 5 
TIME AFTER INJECTION (h) 
IL-.1J3 induces a thermal hyperalgesia in the rat paw. 
Withdrawal latency following i.pl. injection of IL-113 (0.1 - 10 units) and boiled IL-1p. All 
values are expressed as means ± s.e.mean, * p < 0.05 compared to pre - injection control. 
Effects of IL -1/3 on kinin- mediated actions on C- fibres and in behavioural hyperalgesia. 
Kinin B2- mediated effects. 
Bk- induced increase in neural discharge was enhanced lh following i.art. injection of IL -113 
loo u but not boiled IL -113. This was evident at all 3 doses (3, 10 and 30µg, i.a.). Co- 
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3µg, i.a. 101_1g, i.a. 
DOSE BK 
30µg, i.a. 
IÚ-113 enhances Bk- induced increase in neural discharge in knee joint C-fibres, which is 
blocked by IL -ira. 
Effects of Bk (3 - 30 µg, i.a.) is shown in naïve joints, or after intra- articular injection of 
boiled IL -1ß, IL -1f3 100 u and IL -I13 100 u with IL -1 ra 0.1 ,ug. All values are mean ± 
s.e.mean, 'k p < 0.05 compared to boiled IL -1f3- treated joints, Mann Whitney U test. 
In all joints (naïve, boiled IL -1(3- treated, IL -1(3- treated, or IL -1(3 with IL -lra) the Bk- induced 
increase in neural discharge from articular C- fibres was blocked by injection of a kinin B2 














Bk 3014 (n=3-4) 












,ZZ o° o o, 
O' ,o ,oo ,.`Y 
a o. ; ta 
4oó 
w ;. v 
Bk- induced increase in neural discharge in C-fibres innervating untreated or injected knee 
joints is blocked by icatibant. 
Effects are shown for bradykinin 30 pg, i.a. before and following icatibant 10 pgkg -1, i.a.. All 
values are mean ± s.e.mean, p < 0.05 compared to bradykinin effects before injection of the 
antagonists, Mann Whitney U test. 
Intra- articular injection of Bk (0.1 - 10 moles) induced a dose dependent reduction in load 
tolerated by the injected knee. This was significant 1 h after injection when the load tolerated 
had fallen to (83.8 ± 6.9 %) 0.1 nmol, (76.2 ± 5.6 % ) 1 nmol and (53.5 ± 5.6 %) 10 moles and 
was maintained for up to 5 h post- injection : (79.6 ± 7.5 %) 0.1 nmol, (69.2 ± 5.8 %) 1 nmol 
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* -o- saline 0.1m1 (n =16) -- 0.1 nmol (n =13) -y- 1 nmol (n =14) 
-- lOnmol (n =15) 
-3 -2 -1 0 1 2 3 4 5 6 
TIME AFTER INJECTION (h) 
Bk induces a mechanical hyperalgesia in the rat knee joint. 
Effects of i.art. Bk (0.1 - 10 nmol) on load tolerated by the injected knee are shown. All 
values are expressed as means ± s.e.mean, *p < 0.05 compared to pre - injection control. 
The reduction in load tolerated induced by Bk (0.1 and 1 nmole, i.art.) was enhanced 
following co- injection of a sub -threshold dose of IL -1(3 (0.001 u) with a further reduction of 
12.4 % (0.1 nmole) and 26.5 % (1 nmole). However, 5 h after Bk an enhanced reduction of 
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untreated (n =8 -14) 
IL -1 3- treated (n= 15 -26) 
T 
0.1 nmol 1 nmol 0.1 nmol 1 nmol 
T 
1h post -injection 5h post- injection 
DOSE BK ( i.art) 
IL-1,13 enhances the mechanical hyperalgesia induced by Bk. 
The load tolerated following i.art. injection of Bk alone or co- injection with IL -I13 0.001 u is 
shown. All values are expressed as means ± s.e.mean, *p < 0.05 compared to pre - injection 
control. 
The reduction in load tolerated induced by co- injection of Bk (0.1 nmole, i.art.) with sub- 
threshold dose of IL -1[3 (0.001 u) was blocked by co- injection of kinin B1 and B2 receptor 
antagonists. Icatibant (1 and 5 pmoles, i.art.), a kinin B2 antagonist, blocked the reduction in 
load tolerated by the injected knee 5 h following injection, whereas only the higher dose was 
effective 1 h following injection. DesArg9leu8 -Bk (0.5 and 1 nmole, i.art.) also blocked the 
reduction in load tolerated by the injected knee 5 h following injection, whereas only the 
lower dose had any effect 1 h following injection (Figure 5.10.). 
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Figure 5.10 
Mil Bk 0.1 nmol (n=14) 
+ icatibant 1 pmol (n=10) + icatibant 5 pmol (n=18) ® + desArg9leue-Bk 0.5 nmol (n=19) 
+ desArg9leu8-Bk 1 nmol (n=10) 120 -' 
I 
1 
IL-1 0.0001u + Bk (n=27) 
lhour 5 hour 
Kinin B1 and B2 receptor antagonists block the enhanced mechanical hyperalgesia by Bk 
induced by IL-I13 in the rat knee joint. 
Bk (0.1 nmole) with sub - threshold IL -1 ß (0.001 u) alone (open bars, n =27 ), and with 
icatibant (lpmole)(right hatched bars, n =10), Icatibant (5 pinoles, n =18 )(cross hatched 
bars, n = 19), desArg9 leu8 -Bk (0.5nmoles)(left hatched bars, n = 19), and desArg9 leu8 -Bk (1 
nmole)(horizontal bars, n = 10). All values are mean ± s.e.mean. *p < 0.05, compared to 
open bars. 
Bk (1 - 50 nmoles, i.pl) also produced a dose -dependent reduction in withdrawal latency to 
focused radiant heat. This reduction was significant 30 min after injection and was 














-o- saline 0.1 ml(n =6) -- 1 nmol (n =6) 
-A- 5nmol (n =6) 
-y- 10nmol (n =6) -- 50nmol (n =6) 
1 ' 1 ' 1 ' I ' 1 I I I 
-1 0 1 2 3 4 5 6 
TIME AFTER INJECTION (h) 
Bk induces a thermal hyperalgesia in the rat paw. 
Withdrawal latency following i.pl. injection of Bk (1 - 50 nmol) is shown. All values are 
expressed as means ± s.e.mean, * p < 0.05 compared to pre- injection control. 
Co- injection of a sub -threshold dose of IL -113 (0.1 u, i.pl.) did not enhance the reduction in 
withdrawal latency, induced by Bk (1 & 5 nmoles), to a thermal stimulus (Figure 5.12.). 
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untreated (n =6) 
IL -1 ß- treated(n =6T 
80- 
Figure 5.12 
1 nmol 5 nmol 
1h post -injection 
1 nmol 5 nmol 
5 h post- injection 
DOSE BK (i.pl.) 
IL-1J3 does not enhance the Bk- induced thermal hyperalgesia in the rat paw. 
The withdrawal latency following i.art. injection of Bk alone or co- injection with IL -I13 0.1 u 
is shown. All values are expressed as means ± s.e.mean, *p < 0.05 compared to pre- injection 
control. 
Kinin BI- mediated effects 
Intra- articular injection of IL -1(3, but not boiled IL -13, induced a kinin B1 receptor- mediated 
increase in neural discharge. One hour following intra- articular injection of IL -1 f3 100 u, 
desArg9 -Bk increased neural discharge (1.6 ± 0.1 i.p.s.). There was no effect in untreated 
joints (0.3 ± 0.1 i.p.s.) or in those treated with boiled IL -113 (0.4 ± 0.1 i.p.s.). Co- injection of 













untreated(n=11) ® boiled IL-10 100u(n=3) 




/3- induces a desArg9 -Bk mediated increase in neural discharge in knee joint C-fibres, 
which is blocked by IL -lra. 
Effects of desArg9 -Bk (i.a) in untreated, boiled IL -1 )8-treated, IL -1 ß- treated and IL-1p/IL-1 re- 
treated (i.art) joints are shown. All values are mean ± s.e.mean, * p < 0.05 compared to the 
effects in naïve joints, Mann Whitney U test. 
The desArg9 -Bk- induced increase in neural discharge was immediately reduced after i.a. 
injection of desArg9leu8 -Bk (1 mgkg 1) when the B1 mediated increase in discharge decreased 





















+desArg9leu8-Bk 1 mgkg-1(n=3) 
/ 
IL-1D-TREATED KNEE JOINTS 
DesArg9 -Bk- induced increase in neural discharge in IL-Ili-treated knee joints is blocked by 
desArg9 leu8 Bk. 
Effects are shown for desArg9 -Bk 100 pg, i.a. before and following desArg9leu8 -Bk 1 mgkg-1 
All values are mean ± s.e.mean, *p < 0.05 compared to desArg9 -Bk before antagonist, Mann 
Whitney U test. 
DesArg9 -Bk (0.5 - 5 nmoles, i.art.) had no effect on the load tolerated by the injected knee at 













-- saline 0.1m1 (n =16) -- 0.5nmol (n =17) -- 1 nmol (n =16) 
-A- 5 nmol (n =17) 
-3 -2 -1 0 1 2 3 4 5 6 
TIME AFTER INJECTION (h) 
DesArg9- Bk does not induce a mechanical hyperalgesia in naive knee joints. 
Effects of desArg9- Bk(0.5 -5 nmol, i.art) are shown. All values are expressed as means ± 
s.e.mean, *p < 0.05 compared to pre- injection control. 
However, when desArg9 -Bk (1 & 5 nmoles, i.art.) was co- injected with a sub -threshold dose 
of IL -113 (0.001 u) a reduction in load tolerated by the injected knee was observed. This was 
evident at both doses 1 h following injection, when the load tolerated decreased by 22 % 
(1 nmole) and 22 % (5 nmoles). However, 5 h following injection a reduction was only 
observed at the lower dose, when the load tolerated was reduced by 23 % (Figure 5.16.). 
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120 - untreated (n= 16 -17) 
IL-1[3-treated (n= 14 -28) 
0 
Figure 5.16 
1 nmol 5nmol 1 nmol 5nmol 
1h post- injection 5h post- injection 
DOSE desArg9BK (i.art.) 
IL -If3- induces a desArg9- Bk mediated mechanical hyperalgesia in the rat knee joint. 
Effects of desArg9 -Bk alone and co- injection of IL -113 0.001 u with desArg9 -Bk on load 
tolerated are shown. All values are expressed as means ± s.e.mean, *p < 0.05 compared to 
pre- injection control. 
The reduction in load tolerated induced by co- injection of desArg9 -Bk (1 nmole, i.art.) with 
IL -113 (0.001 u) was blocked when desArg9leu8 -Bk (0.5 & 1 nmole, i.art.) was co- 
administered. This was evident 1 h and 5 h after injection. The B2 antagonist, Icatibant (5 
pmoles, i.art.) had no effect on the reduction in load tolerated by the injected knee (Figure 
5.17.) 
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= desArg9Bk 1 nmoles (n=16) n IL-1 + desArg9Bk (n=10) ® + icatibant 5 pmol (n=13) E;:;; + desArg91eu8-Bk 0.5 nmol (n=20) ® + desArg91eu8-Bk 1 nmol (n=10) 
120 - * 
Figure 5.17 
* 
1 hour 5 hour 
Kinin B1, but not B2 receptor antagonists block the mechanical hyperalgesia induced by 
desArg9 -Bk in the rat knee joint. 
Effects of desArg9 -Bk (1 nmole) with sub- threshold IL -l13 (0.001 u) alone and with icatibant 
and desArg9 leu8 -Bk on load tolerated are shown. All values are mean ± s.e.mean. *p < 
0.05, compared to open bars. 
DesArg9 -Bk (5 - 50 nmoles, i.pl.) had no effect on the withdrawal latency to focused radiant 















-o- saline 0.1 mI(n =6) -- 5nmol(n =6) -- l Onmol(n =6) 
-A- 50nmol(n =6) 
I I 
-3 -2 -1 0 1 2 3 4 5 6 
TIME AFTER INJECTION (h) 
desArg9 -Bk does not induce a thermal hyperalgesia in naive rat paws. 
Effects of i.pl. desArg9 -Bk (5 - 50nmol) on withdrawal latency are shown. All values are 
expressed as means ± s. e. mean, * p < 0.05 compared to pre- injection control. 
When desArg9 -Bk (10 & 50 nmoles, i.pl.) was co- injected with a sub -threshold dose of Th -113 
a reduction in withdrawal latency to a thermal stimulus was observed. This was evident at 
both doses 1 h following injection, when the withdrawal latency was reduced by 35.6 % (10 
nmoles) and 37.5 % (50 nmoles) and also 5 h following injection when the latency was 




untreated (n =6) 
IL-1f1-treated (n =6) 
T T 
10 nmoles 50 nmoles 10 nmoles 50 nmoles 
1 h post- injection 5 h post- injection 
DOSE desArg9 -BK (i.pl.) 
IL -113 induces a desArg9 -Bk mediated thermal hyperalgesia in the rat paw. 
Effects of desArg9 -Bk alone and co- injection of IL -If3 0.1 u with desArg9 -Bk on withdrawal 
latency are shown. All values are expressed as means ± s.e.mean, *p < 0.05 compared to 
pre- injection control. 
The reduction in withdrawal latency induced by co- injection of desArg9 -Bk (50 nmoles, i.pl.) 
with IL -1ß (0.1 u) was blocked when co- administered with desArg9leu8 -Bk (1 & 10 nmole, 
i.pl.). This was evident 1 h and 5 h after injection. The B2 antagonist, icatibant (5 pmoles, 
i.art.) had no effect on the reduction in withdrawal latency in response to thermal stimulus of 
the injected paw (Figure 5.20.) 
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Figure 5.20 
desArg9Bk 50 nmoles (n=6) IL-1 0.1 u + desArg9Bk (n=6) 
+ icatibant 5 pmol (n=6) ;;;;7 +desArg9leu8-Bk 1 nmol (n=6) 








Kinin B1, but not B2 
1 hour 5 hour 
receptor antagonists block the thermal hyperalgesia induced by 
desArg9 -Bk in the rat paw. 
Effects of desArg9 -Bk (50 nmole) with sub -threshold IL -1 /3 (0.1 u) alone and with icatibant 
and desArg9 leu8 -Bk on withdrawal latency are shown. All values are mean ± s.e.mean. *p < 
0.05, compared to open bars 
5.4 Discussion. 
These results provide evidence that local injection of IL -113 increases C -fibre activity in vivo 
and can induce both mechanical and thermal hyperalgesia. They also show that IL-113 can 
sensitise nociceptors to Bk and provide further evidence for a role for IL -1(3 in the induction 
of a B1 mediated hyperalgesia in inflamed knee joints. 
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Local injection of IL -113 increased neural discharge from C- fibres innervating the rat knee 
joint and induced a mechanical and thermal hyperalgesia. The doses used to induce an 
increase in firing from nociceptors were higher than those used to induce a behavioural 
hyperalgesia. The doses used however, were comparable to those used to activate cutaneous 
C- fibres in the saphenous nerve (Fukuoka et al., 1994). Fukuoka also reported a similar delay 
to onset of action and duration following local administration of the cytokine. 
A behavioural hyperalgesia has been observed with similar doses in a variety of animal 
models. In the Randall -Selitto paw -withdrawal test, IL-113 induced mechanical hyperalgesia 
which was mediated by release of prostaglandins (Cunha et al., 1992). Mechanical and 
thermal hyperalgesia following inflammation or IL -1ß administration has also been shown to 
involve kinin B1 and B2 receptors as well as prostaglandins (Davis & Perkins, 1994; Perkins 
& Kelly, 1994). 
IL -13 also increased responses to Bk in both neural recordings and mechanical hyperalgesia, 
but not in thermal hyperalgesia. IL -1(3 can upregulate kinin B2 receptors and enhance 
responses to kinins (Galizzi et al., 1994; Lerner & Modeer, 1991). These enhanced responses 
may be due to release of prostaglandins which have been shown to sensitise nociceptors to Bk 
(Weinreich, 1986; Birrell et al., 1991). Such an effect may be further enhanced as IL -113 can 
act in synergy with Bk to release prostanoids from cells including fibrobasts (Sundqvist & 
Lerner, 1996; Lerner & Modeer, 1991 ) and synovial cells(O'Neil & Lewis, 1989). The 
enhanced responsiveness to Bk in mechanical hyperalgesia is observed 1 hour and 5 hours 
after injection with the lower dose of Bk, however this is only observed at the early time point 
with the higher dose of Bk. It could be that 5 hours after injection the higher dose of Bk could 
synergise sufficiently with IL -113 to release mediators which regulate the inflammatory 
process or associated hyperalgesia. In previous chapters it was observed that in both inflamed 
ankle joints and knee joints the increase in neural discharge induced by Bk had a tendency to 
be lower than that observed in normal joints. There could be several reasons for this. Both 
Bk and IL -113 can lead to formation of nitric oxide which the present studies have shown to 
reduce Bk responses in arthritic ankle joints and has been shown to be involved in 
desensitisation of the Bk receptor. IL -113 can also release several anti -inflammatory cytokines 
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including, IL -4, IL -10 and IL -13 which have the ability to modulate the effects of IL -113. 
It could also be that Bk is degraded more rapidly in inflammation. Levels of kininases have 
been shown to be elevated in inflammatory conditions, which may be the case at the later 
period of the experiment. Somewhat surprising results were obtained in the thermal 
experiments as no increase in Bk responsiveness was observed when administered with IL -113. 
As yet there is no explanation for this, but it may be that there is a difference between thermal 
and mechanical stimulus or there is a difference between the paw and the knee joint, for 
example, Bk may be broken down more rapidly within the paw. To investigate this a 
mechanical stimulus could be used in the paw and compared to the results obtained using the 
thermal stimulus. 
The 1L -113- induced kinin B 1- mediated increase in neural discharge, mechanical hyperalgesia 
and thermal hyperalgesia observed here is consistent with previous studies relating this 
cytokine to B1 kinin receptor induction. IL-113 has been shown to induce B1 mediated 
responses in blood vessels, an action which appears to involve induction of the receptor as it 
can be blocked by cyclohexamide, a protein synthesis inhibitor. It has also been shown to 
induce a B1 mediated mechanical and thermal hyperalgesia in behavioural models (Davis & 
Perkins, 1994; Perkins & Kelly, 1994). As discussed previously, there is, as yet, no evidence 
of B1 receptors on sensory neurons, and the delay to onset of action of desArg9 -Bk suggests 
that the B1 mediated increase in neural discharge and behavioural hyperalgesia is indirect, 
possibly mediated through release of inflammatory mediators from non -neuronal cells such as 
macrophages, fibroblasts, synovial cells, endothelial cells and smooth muscle cells (Tiffany & 
Burch, 1989; Lerner & Modeer, 1991; Bathon et al., 1989; Cahill et al., 1988; Galizzi et al., 
1994). IL -1 f3 can synergise with kinin B1 agonists to release prostaglandins from fibroblasts 
(Lerner & Modeer, 1991). In the mechanical hyperalgesia model although IL -113 induced a B1 
mediated hyperalgesia with the lower dose at both the early and late time point, the higher 
dose was only hyperalgesic at the 1 hour time point. The reasons for this may be the same as 
discussed with Bk. 
These results provide evidence for a role of IL -10 in hyperalgesia. They also indicate a role 
for IL -113 in increasing the responses to desArg9 -Bk and Bk. The results also suggest there 
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may be a difference between acute and a more persistent inflammation as with higher doses of 
kinins no enhancement of response was observed at the later time points or indeed in arthritic 
knee joints - Bk has a tendency to induce a smaller increase in neural discharge than observed 
in normal joints. This may be due to an autoregulation of the inflammatory process with anti - 
inflammatory or anti -nociceptive modulation occurring. 
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6. THE ROLE OF PROSTAGLANDINS IN IL -1ß MEDIATED HYPERALGESIA 
AND MODULATION OF KININ ACTIVITY: ELECTROPHYSIOLOGICAL AND 
BEHAVIOURAL STUDIES. 
6.1 Introduction. 
The pro- inflammatory cytokine, Th -113, has a multitude of pro -inflammatory actions. When 
IL -113 binds to its receptor, the IL -1RI receptor, it releases arachidonic acid via activation of 
phospholipase A2 (Gronich et al., 1994) with subsequent production of prostaglandins from a 
variety of cells including macrophages, endothelial cells, fibroblasts and synovial cells 
(Billingham, 1987). As well as producing prostanoids directly, IL -113 also upregulates the 
inducible cyclooxygenase enzyme (COX -2) in human synovial cells (Bathon et al., 1994) 
resulting in increased prostaglandin synthesis. The role of prostaglandins in IL -113 mediated 
hyperalgesia is somewhat confusing as indomethacin has been shown to reduce the 
hyperalgesic effects in some studies (Cunha et al., 1992; Davis & Perkins, 1994), but has no 
effect in others (Follenfant et al., 1989). However, studies in the cat knee joint have shown 
that both PGE2 and PGI2 excite and sensitise a large proportion of C- fibres (Schepelmann et 
al., 1992) suggesting that prostaglandins have the ability to produce hyperalgesia. 
Bk acting via B2 receptors on non -neuronal cells including fibroblasts, synovial cells and 
smooth muscle cells can also activate membrane phospholipase A2 resulting in the production 
of prostanoids (Bareis et al., 1983; Burch & Axelrod, 1987; Bathon et al., 1989; Galizzi et al., 
1994). Prostaglandins can increase pain to injection of Bk in human skin and veins(Kindgen- 
Milles, 1995) and can sensitise sensory nerves to Bk in the cat knee joint (Schepelmann et al., 
1992) and rat ankle joint (Birrell et al., 1991). The mechanism which probably underlies this 
sensitisation is as follows: prostaglandins acting on prostanoid receptors can then activate 
adenylate cyclase, thereby raising levels of cAMP which in turn inhibits Ca + +- dependent K+ 
permeability. This reduces the post -spike hyperpolarisation which is K+ dependent and can 
lead to an increase in excitability of the cell (Weinreich, 1986). 
As with the B2 receptor, activation of the B 1 receptor activates membrane bound 
phospholipase A2 with subsequent production of prostanoids from endothelial cells, smooth 
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muscle cells, fibroblasts and macrophages (D'Orleans -Juste et al., 1989; Galizzi et al., 1994; 
Marceau & Tremblay, 1986; Tiffany & Burch, 1989; Marceau et al., 1995). IL -113 can also 
synergise with Bi receptor agonists on fibroblasts to induce production of prostaglandins 
(Lerner & Modeer, 1991). 
These experiments have, therefore, investigated the role of prostaglandins, using an inhibitor 
of COX, indomethacin, in IL-1n-induced increase in neural discharge The role of prostanoids 
in the modulation of kinin B i and B2- mediated effects, by IL -13 was also investigated. 
6.2 Methods. 
These were as described in sections 2.3. and 5.2. (neural experiments) and 2.4 (behavioural 
experiments). In neural experiments indomethacin was administered systemically (i.a.) 30 
minutes before i.art. injection of the algesic agents into knee joints. In the behavioural 
experiments indomethacin was injected subcutaneously with an injection volume of 0.1m1 in 
all cases. 
6.3 Results. 
In the behavioural experiments discussed in this section, the pre- injection control values were 
as follows. The load tolerated before i.art. injection was 93.2 ± 1.1g (range: 70 - 146g, n = 
161). The withdrawal latency in the thermal hyperalgesia model before i.pl. injection was 
10.1 ± 0.3 s (range: 6.7 - 14.8 s, n = 47). 
Effects of indomethacin on IL -113- induced effects on the neural discharge of C- fibres and on 
behavioural hyperalgesia. 
When indomethacin (1 mgkg 1, i.a.) was administered 30 min prior to IL -113 (100 u, i.art.) the 
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Indomethacin blocks IL -Iß- induced increase in neural discharge. 
(top graph) Effects of IL -1 f3 100 u alone and (lower graph) following pre -treatment (30 min) 
with indomethacin 1 mgkg-1, i.a. on neural discharge are shown. Bargraphs showindividual 
expetiments and their respective mean ± s.e.m., * p < 0.05 compared to indomethacin treated, 
Wilcoxan matched pairs test. 
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In the behavioural hyperalgesia experiments, pre- treatment (30 min.) with indomethacin 
(lmgkg 1, s.c.) blocked the IL -1(3- induced (10 u, i.art.) reduction in load tolerated by the 
injected knee throughout the time course of the experiment. Boiled IL -113 had no effect by 
itself nor did indomethacin influence the tolerated load when given 30 min. prior to boiled IL- 











-- IL-1 ß 10u(n=14) * 
-A- IL-1 ß/indomethacin 1 mgkg-1(n=10) 
-*- boiled IL-1 ß/indomethacin(n=10) 
30 I 
-3 -2 -1 0 1 2 3 4 5 6 
TIME AFTER INJECTION (h) 
Indomethacin blocks IL-1/3-induced mechanical hyperalgesia. 
Effects of IL -1/3 10 u alone, following pre -treatment (30 min, s.c.) with indomethacin and 
indomethacoin pre- treatment followed by boiled IL -1,6 are shown. All values are mean ± 
s.e.m., 'r p < 0.05 compared to pre- injection control. 
Pre -treatment (30 min.)with indomethacin (1 mgkg1, s.c.) also blocked the IL -113 (10 u, i.pl.)- 
induced reduction in withdrawal latency to a focused radiant heat throughout the time course 
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TIME AFTER INJECTION (h) 
Indomethacin blocks IL -1 /3- induced thermal hyperalgesia. 
Effects of i.pl. IL -1ß 10 u alone and following pre -treatment (30 min, s.c.) with indomethacin 
on withdrawal latency are shown. All values are mean ± s.e.m., * p < 0.05 compared to pre - 
injection control. 
Effects of indomethacin on IL -1/3- induced effects on Bk- induced activation of C- fibres and Bk- 
induced mechanical hyperalgesia. 
The enhancement of C -fibre activity by Bk in joints pretreated with IL -1(3 was prevented by 
pre- treatment (30 min.) with indomethacin (1 mgkg 1, i.a.). The increase in neural discharge 
observed in indomethacin pre- treated rats was no different to that observed in untreated knee 
88 
joints (Figure 6.4.). 
Figure 6.4 
o 
untreated(n=11) 1= IL-113100u (n=4) 
+indomethacin 1mgkg-1(n=4) 
3 pg 10 pg 
DOSE BK (i.a.) 
30 pg 
Indomethacin blocks IL -1 13-induced increase in C-fibre responsiveness to Bk. 
Effects of i.a. Bk in untreated knee joints IL -lß- treated joints: 100 u, i.art. and following pre- 
treatment (30 min, i.a.) with indomethacin 1 mgkg -1, i.a. are shown. All values are mean ± 
s.e.m., * p < 0.05 compared to untreated knee joint control. 
The enhanced reduction in load tolerated observed 1 and 5 h following co- injection (i.art.) of a 
sub -threshold dose of IL -1(3 (0.001 u) and Bk (0.1 nmol) was blocked by pre- treatment (30 














untreated(n=13) %//, IL-1130.001u (n=26) 
+indomethacin 1mgkg-1(n=20) 
1 hour 5 hour 
1h post- injection 5h post- injection 
Effect of indomethacin on i.art. IL- 1ß- induced enhanced mechanical hyperalgesia induced 
by Bk. 
Effects of Bk 0.1 nmol, i.art. alone, and co- injected with sub -threshold IL -Iß and following 
pre- treatment (30 min, s.c.) with indomethacin on load tolerated are shown. All values are 
mean ± s. e. m., * p < 0.05 compared to open bars. 
Effects of indomethacin on IL -1/3- induced responses of C- fibres to desAr ,g9 -Bk- induced on 
desAr,9 -Bk- induced mechanical and thermal hyperalgesia. 
Pre -treatment (30 min.) with indomethacin (1 mgkg ', i.a.) also blocked the enhanced 
responsiveness of C- fibres to i.a. desArg9 -Bk in IL -113- treated knee joints. There were no 
effects of desArg9 -Bk in either untreated knee joints or in those rats which had been pre- 













control (n =4) ® IL -1 ß 100 units (n =4) 
+ indomethacin 1 mgkg -1 (n =4) 3. 
desArg9Bk 
100 µg 
Indomethacin blocks IL -Iß- induced desArg9 -Bk- mediated increase in neural discharge. 
Effects of i.a. desArg9 -Bk in untreated knee joints IL-10-treated joints: 100 u, i.art. and 
following pre - treatment (30 min, i.a.) with indomethacin 1 mgkg 1, i.a. are shown. All values 
are mean ± s.e.m., * p < 0.05 compared to untreated knee joint control. 
The reduction in load tolerated 1 and 5 h following co- injection (i.art.) of a sub -threshold dose 
of IL -1(3 (0.001 u) and desArg9 -Bk (1 nmol) was not blocked by pre- treatment (30 min.) with 
indomethacin (1 mgkg -1) [Figure 6.7.]. 
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1 h post -injection 
5 hour 
5h post- injection 
Indomethacin has no effect on IL -1 ß- induced desArg9 -Bk- mediated mechanical 
hyperalgesia. 
desArg9 -Bk 1 nmol, i.art. ( open bar, n = 16) alone, and co- injected with sub -threshold IL-1ß, 
0.001 u (hatched bars, n = 28) and IL -1 ß with Bk following pre -treatment (30 min) with 
indomethacin 1 mgkg ', s.c. (cross hatched bars, n = 18). All values are mean ± s.e.m., p < 
0.05 compared to open bars. 
The reduction in withdrawal latency to a thermal stimulus following a co- injection (i.pl.) of a 
sub -threshold dose of IL-1I3 (0.1 u) and desArg9 -Bk (50 nmol) was prevented by pre- treatment 
(30 min) with indomethacin (1 mgkg ', s.c.) but only for 2h following injection of desArg9 -Bk 
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-- untreated (n =6) -- IL-113 0.1u (n =6) -- +indomethacin 1 mgkg-1(n =6) 
1 I I 
-1 0 1 2 3 4 5 
TIME AFTER INJECTION (h) 
Indomethacin only blocks IL -Iß- induced desArg9 -Bk- mediated thermal hyperalgesia 60 
minutes after injection of the B1 antagonist. 
Effects of desArg9 -Bk 50 nmol, i.pl. alone, and co- injected with sub -threshold IL -1 ß, 0.1 u 
and following pre -treatment (30 min, s.c.) with indomethacin on withdrawal latency are 
shown. All values are mean ± s.e.m., * p < 0.05 compared to closed square. 
6.4 Discussion. 
These results provide evidence that IL -lß- induced increase in neural discharge from C- fibres 
in -vivo and behavioural hyperalgesia is mediated via release of prostanoids. The release of 
prostanoids is also responsible for the IL -1(3- induced enhancement of Bk- induced activation 
of C- fibres and mechanical hyperalgesia. However, prostanoids only seem to be involved in 
the IL- l (3- induced kinin B i receptor- mediated increase in neural discharge, but not the IL -113- 
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induced kinin B i receptor- mediated mechanical and thermal hyperalgesia. 
Pre -treatment with indomethacin 1 mgkg 1, a dose which is within the same range as 
previously published 1D50 doses, e.g, 0.8mgkg"' (Tonussi & Ferreira, 1992). IL -1ß- induced 
activation of C- fibres and behavioural hyperalgesia. This is consistent with previous studies 
which showed that indomethacin blocked IL -lß- induced behavioural hyperalgesia (Cunha et 
al., 1992) and PGE2 and PGI2 have both been shown to excite and sensitise C- fibres. Both 
prostaglandins have a similar action although the sensitisation induced by PGI2 has a longer 
duration (Schepelmann et al., 1992; Birrell et al., 1991). IL -1ß not only releases prostanoids 
from inflammatory cells (Billingham, 1987) but also induces formation of COX -2 (Bathon et 
al., 1994). Indomethacin inhibits both COX -1 and COX -2 (approximately 1.7 times more 
potent at inhibiting the former (Ogino et al., 1997)), thus reducing formation of prostanoids 
and thus hyperalgesia induced by IL -1ß (Vane & Botting, 1996). 
Prostaglandins, in particular PGE2 and PGI2, have also been show to sensitise joint 
nociceptors to Bk (Scheppleman et al., 1992; Birrell et al., 1991). This is consistent with our 
findings that indomethacin blocked IL -113- induced enhancement of Bk responses on knee joint 
C- fibres and IL- 1 ß- induced enhancement of Bk mediated mechanical hyperalgesia. 
Prostanoid EP2 receptors have been shown to be involved in the sensitisation of nociceptors to 
heat (Kumazawa et al., 1994) whereas EP3 receptors have been shown to sensitise nociceptors 
to Bk (Kumazawa et al., 1993). The mechanism of sensitisation is probably as follows. 
When prostanoids bind to their receptors this activates adenylate cyclase resulting in 
production of cAMP and activation of protein kinase A and inhibition of Ca + +- dependent K+ 
ion channel (Wang et al., 1996). 
Indomethacin blocks kinin B I mediated increase in neural discharge induced by IL -1 ß but is 
ineffective in IL -113- induced kinin B1 receptor mediated mechanical hyperalgesia and only 
effective for up to 2 hours in kinin B 1 mediated thermal hyperalgesia. This suggests the 
increase in neural discharge and the behavioural hyperalgesia induced by B1 receptor 
activation have different underlying mechanisms. One possibility are leukotrienes, products 
of the lipoxygenase pathway. Kinin B1 agonists have been shown to release LTB4 from 
macrophages (Sato et al., 1996) and LTB4 has been shown to sensitise nociceptors to 
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mechanical and thermal stimulus (Martin et al., 1987). 
These results show that prostaglandins are involved in the 1L -113- induced increase in neural 
discharge from C- fibres and behavioural hyperalgesia and IL -1(3- induced enhancement of 
kinin mediated increase in neural discharge and B2- mediated mechanical hyperalgesia. This, 
however, is not the only mechanism as indomethacin has no effect on IL -1 [3- induced kinin B1 
mediated behavioural hyperalgesia suggesting that more than one pathway is involved. 
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7. THE MODULATORY ROLE OF IL -4 AND IL -10 ON IL -113 MEDIATED 
HYPERALGESIA AND MODULATION OF KININ ACTIVITY IN BEHAVIOURAL 
STUDIES. 
7.1 Introduction. 
The previous studies have explored the modulation of both C -fibre activity and behavioural 
hyperalgesia in inflamed joints. In arthritic knee joints Bk- induced increase in neural 
discharge had a tendency to be lower than in normal joints. Also, in behavioural experiments, 
regarding the modulation of kinin activity by IL -113, some unusual results were observed. IL- 
113 did not enhance hyperalgesia, when higher doses of kinins were used, at later time points 
during experiments. 
Although most cytokines studied to date are primarily thought of as pro -inflammatory, several 
cytokines have been shown to possess anti -inflammatory properties (Burger & Dayer, 1995). 
Their actions appear to involve the regulation or modulation of the actions of inflammatory 
cytokines, particularly IL -113. Three such cytokines; IL -4, IL -10 and IL -13, have been shown 
to be released from activated T- cells, monocytes and mast cells (MacNeil et al., 1990; Spits et 
al., 1992; de Waal Malefyt et al., 1991; Burd et al., 1995), all cell types prevalent in 
inflammation.. 
IL -4 and IL -13 act on receptors which bear similarities to each other (Vita et al., 1995; Smerz- 
Bertling & Duschl, 1995). It is not surprising then, that they have similar actions; both inhibit 
production of inflammatory cytokines including IL -113, from monocytes (Essner et al., 1989; 
te Velde et al., 1990; Minty et al., 1993), upregulate the production and relase of IL -lra 
(Vannier et al., 1992; Vannier et al., 1996) and IL -1RII (Colotta et al., 1993; Colotta et al., 
1996; Girard et al., 1996). The actions by IL -10 are somewhat similar to those of IL -4; 
including downregulation of IL -1 production and upregulation of IL -lra production (Jenkins 
et al., 1994). However, IL -4 and IL -10 appear to differ in some ways with respect to 
regulation of inflammatory mediators. IL -4, but not IL -10, reduces PGE2 release from 
synoviocytes (Dechanet et al., 1995) and TNFa release from monocytes (Joyce et al., 1994). 
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These studies investigated whether these putative `anti -inflammatory' cytokines could 
modulate IL-113 induced mechanical and thermal hyperalgesia as well as the RAP-induced 
enhancement of kinin activity. To accomplish this we made use of two such anti - 
inflammatory cytokines. Bearing in mind the similarities between IL-4 and IL-13 and the 
differences observed between IL -4 and IL -10, it was decided to look at the effects of the latter 
two. 
7.2 Methods. 
As described in section 2.4. In these experiments either IL-4 or IL-10 was injected 
concomitantly with: IL -113; IL -113 and desArg9 -Bk; or IL-1(3 and Bk. 
7.3 Results. 
In the behavioural experiments discussed in this section, the pre -injection control values were 
as follows. The load tolerated before hart. injection of IL -1[3, IL -113 and desArg9 -Bk., or IL-113 
and Bk was 92.7 ± 0.8 g (range: 70 - 146g, n = 260). The withdrawal latency in the thermal 
hyperalgesia model before i.pl. injection was 10.3 ± 0.3 s (range: 6.5 - 15 s, n = 76). 
Effects of IL -4 and IL-10 on IL-1ß-induced effects in behavioural hypzralgesía. 
IL -4 (1 & 10 ng, i.art.) co- injected with IL-1[3 alleviated the reduction in load tolerated by the 
injected knee seen with I -1 13, although this was not dose -dependent at the two doses used 
here. IL-4 co- injected with boiled IL-113 had no effect on the load tolerated by the injected 
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-- IL-1 10u(n=14) -I- + IL-4 1 ng(n=10) 
-A- + IL-4 10ng(n=9) -- boiled IL-1/ IL-4 10ng(n=10) 
, , , , , , , , , 
-3 -2 -1 0 1 2 3 4 5 6 
TIME AFTER INJECTION (h) 
IL-4 reduces IL -Il3- induced mechanical hyperalgesia. 
Effects of i.art. IL -1ß alone, co- injected with IL -4 1 ng and lOng and IL -4 10 ng co- injected 
with boiled IL -1/3 on load tolerated are shown. All values are mean ± s.e.m., p < 0.05 
compared to IL -1 0 alone. 
IL -10 (1 & 10 ng, i.art.) co- injected with IL -10 also prevented the reduction in load tolerated 
by the injected knee following IL -1 (3 and, as with IL -4, this was not dose -dependent. IL -10 
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-A- + IL-10 10ng(n=10) 
-D- boiled IL-1/ II-10 10ng(n=10) 50 
40 
-3 -2 -1 0 1 2 3 4 5 
TIME AFTER INJECTION (h) 
IL -10 reduces IL -1 ß induced mechanical hyperalgesia. 
Effects of i.art. IL -Iß alone, co- injected with IL -10 1 ng and 10 ng and IL -10 10 ng co- 
injected with boiled IL-1p on load tolerated are shown. All values are mean ± s.e.m., * p < 
0.05 compared to IL -1 ß alone. 
The reduction in withdrawal latency induced by i.pl. IL -1(3 (10 u) to a thermal stimulus was 
prevented by co- injection with IL -4 (10 ng). IL -4 had no significant effect on paw 
withdrawal latency when it was co- injected with boiled IL -1(3 (Figure 7.3.). 
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-A- IL-1(3 10u(n=11) 
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TIME AFTER INJECTION (h) 
IL -4 reduces IL-113-induced thermal hyperalgesia. 
Effects of i.pl. IL -10 alone, co- injected with IL -4 lOng and IL -4 10 ng co- injected with boiled 
IL -1/3 on withdrawal latency are shown. All values are mean ± s.e.m., * p < 0.05 compared 
to IL -1 ß alone. 
The reduction in withdrawal latency induced by i.pl. IL -113 (10 u) to a thermal stimulus was 
prevented by co- injection with IL -4 (10 ng), but only for lh following injection. IL -10 had 























-A- IL-1(3 10u(n=11) 
--+IL-10 10ng(n=6) -- IL-10/boiled IL-1 ß(n=6) 
-1 0 1 2 3 4 
TIME AFTER INJECTION (h) 
IL -10 only reduces IL-1 ß-induced thermal hyperalgesia for one hour. 
5 
Effects of i.pl. IL -Iß alone, co- injected with IL -10 lOng and IL -10 10 ng co- injected with 
boiled IL -1ß on withdrawal latency are shown All values are mean ± s.e.m., * p < 0.05 
compared to IL -1 ß alone. 
Effects of IL -4 and IL -10 on IL -1/3- induced effects on Bk- induced responsiveness in 
behavioural hyperalgesia. 
The enhancement of Bk- induced (0.1nmol) hyperalgesia by IL -1E3 (0.001 u, i.art.) was 








1 hour 5 hour 
IL -4 and IL -10 block IL -1 /3- induced enhanced Bk- mediated mechanical hyperalgesia. 
Effects of IL-113 0.001 u with Bk 0.1 nmol and co- injected with IL -4 10 ng or IL-10 10 ng on 
load tolerated are shown. All values are mean ± s.e.m., * p < 0.05 compared to open bars 
Effects of IL -4 and IL -10 on IL -Iß- induced effects on desArg9 -Bk- induced responsiveness in 
behavioural hyperalgesia. 
Co- injection of IL -4 or IL -10 blocked the mechanical hyperalgesia induced co- injection of 
desArg9 -Bk 1 nmol and IL -113 0.001 u, i.art throughout the course of the experiment (Figure 
7.6). 
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1 hour 5 hour 
IL -4 and IL -10 block IL -1 ß- induced desArg9 -Bk- mediated mechanical hyperalgesia. 
Effects of IL -1 ß 0.001 u with desArg9 -Bk 1 nmol and co- injected with IL -4 10 ng or IL -10 10 
ng on load tolerated are shown. All values are mean ± s.e.m., * p < 0.05 compared to open 
bars 
The thermal hyperalgesia induced by co- injection desArg9 -Bk 50 nmol and IL -1(3 0.1 u, i.pl. 
was prevented by IL -4 10 ng throughout the course of the experiment However, IL -10 10 ng 
only alleviated the hyperalgesia induced by co- injection of desArg9 -Bk 50 nmol and IL -13 
0.1 u, i.pl, 1 h after injection (Figure 7.7.). 
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1 hour 5 hour 
IL -4 and IL -10 block IL-1 ß-induced desArg9 -Bk- mediated thermal hyperalgesia with 
differing time courses. 
Effects of IL-113 0.1 u with desArg9 -Bk 50 nmol and co- injected with IL -4 10 ng or IL -10 10 
ng on load tolerated are shown. All values are mean ± s.e.m., * p < 0.05 compared to open 
bars 
7.4 Discussion 
Both IL -4 and IL -10 reduced the hyperalgesia produced by local injection of IL -13, as well as 
enhancement of responses to Bk and desArg9 -Bk induced by IL -1(3 in the mechanical 
hyperalgesia model. However differences in the time course of effect of IL -4 and IL -10 were 
observed in the thermal hyperalgesia model. IL -4 reduced both IL -1[3- induced hyperalgesia as 
well as the induction of a kinin B 1 receptor- mediated hyperalgesia by IL-113 for up to 5h 
104 
following treatment. However, IL -10 only reduced these responses for the first hour 
following injection. 
Both IL -4 and IL -10 down -regulate production of inflammatory cytokines, including IL -113, 
from activated monocytes (Essner et al., 1989; to Velde et al., 1990; Jenkins et al., 1994) thus 
reducing any increased release of cytokines induced by either IL -l(3, itself, or kinins 
(Dinarello et al., 1994; Tiffany & Burch, 1989). IL -10 and IL -4 also up- regulate synthesis and 
release of an endogenous antagonist to IL -1, IL -1 ra. IL- l ra competes with IL-113 for the IL- 
1RI but once it binds it is unable to transduce a signal (Evans & Robbins, 1994), thus acting 
as an endogenous antagonist of IL -1[3. 
IL -4 has a longer duration of action in thermal hyperalgesia than IL -10 but not in mechanical 
hyperalgesia. There is no in -vivo evidence relating to the half- life of IL -4 and IL -10, but a 
possible explanation for the different time courses could be that IL -10 is broken down more 
rapidly than IL -4 in the paw. The differences between the two cytokines arise with respect to 
increased synthesis and release of soluble IL -1R11. IL -4 increases expression and release of 
the soluble form of IL -1RII (Colotta et al., 1993) and this receptor can bind preferentially and 
irreversibly to IL -113 (Colotta et al., 1994). Increased levels of this receptor would thus mop 
up the excess IL -1(3 and act as a decoy receptor reducing the biological activity of IL-1f3. IL- 
4, but not IL -10 also regulated the production of inflammatory mediators, including PGE2 
from synoviocytes activated by IL -113 (Dechanet et al., 1995). Thus, IL -4 has the ability to 
reduce the effects of IL -1( in a more diverse way than IL -10. Although this doesn't explain 
fully the difference in duration of action between IL -4 and IL -10, it does illustrate that they 
have different mechanisms by which they reduce the biological effects of IL -113. 
These results show that two anti -inflammatory cytokines can modulate the hyperalgesia 
induced by IL -113 and may play a role in modulating inflammatory hyperalgesia. These 
endogenously released mediators may play an autoregulatory role in the hyperalgesia and 
inflammation in clinical coditions such as rheumatoid arthritis. 
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8. DISCUSSION AND CONCLUSIONS 
The future direction for the treatment of inflammatory joint diseases and the associated 
hyperalgesia appears to be focusing on the role of inflammatory mediators, which are 
increased in the synovial fluid of rheumatoid joints. In order to establish the exact role these 
mediators have in the associated hyperalgesia use will need to be made of experimental 
animal models. In this thesis I have used both electrophyisiological techniques (recording 
from afferent C- fibres) and behavioural hyperalgesia models to study the effects and 
interactions of two classes of inflammatory mediators, namely kinins and IL -113. 
These studies have shown that in inflammation, kinin B1 receptors, which are not present (or 
if present, not functional) under normal physiological conditions, become important in the 
hyperalgesia associated with inflammation. From these present studies it is not possible to 
state that this is a direct effect via action on B1 receptors located on sensory neurones, 
although it does seem improbable as studies have shown that there was no evidence of B 
receptors on sensory neurones in cultured dorsal root ganglion cells following either injection 
Freund's adjuvant into neonatal rats (i.p.) or incubation of the cultured dorsal root ganglion 
cells with IL -113 (Davis et al., 1996). It seems more likely that this B1 mediated hyperalgesia 
is an indirect effect, mediated via B i receptors located on inflammatory cells. Such cells may 
include macrophages, fibroblasts and synovial cells (Tiffany & Burch, 1989; Lerner & 
Modeer, 1991; Bathon et al., 1989). Activation of B1 receptors on these cells would release 
inflammatory mediators which could act directly on nociceptors to alter their sensitivity and 
produce hyperalgesia. 
Possible mediators released from inflammatory cells by kinin B1 receptor agonists are the 
cytokines. IL -1(3 has been shown to activate sensory neurones (Fukuoka et al., 1994) and can 
induce behavioural hyperalgesia (Davis & Perkins, 1994; Perkins & Kelly, 1994) which is 
consistent with the results presented in this thesis. This cytokine may therefore have a pivotal 
role in sensitising nociceptors. IL -1(3 is also involved in the induction of further B i receptors, 
an action that involves protein synthesis as it is blocked by cyclohexamide (De Blois et al., 
1991), which is consistent with results in this thesis. In these studies IL -113 also enhanced the 
responses induced by Bk. In behavioural studies the enhanced Bk- induced hyperalgesia is 
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blocked by both B2 and B1 receptor antagonists, suggesting that the enhanced hyperalgesia is 
mediated partly via B1 receptors by the Bk breakdown product desArg9 -Bk. In neural 
experiments, this is less clear as the enhanced responses were completely blocked by a B2 
receptor antagonist. It would be interesting to investigate whether injection of a B1 antagonist 
before IL -113 would prevent the enhancement of Bk- induced hyperalgesia. 
IL -i(3 releases other cytokines including IL -113 itself. IL -113 also produces hyperalgesia via 
indirect mechanisms. For example, IL -113 can release prostanoids which have been shown to 
be involved in behavioural hyperalgesia (Cunha et al., 1992) and PGE2 and PGI2 both activate 
knee joint C- fibres and sensitise them to Bk (Schepelmann et al., 1992). IL -1 and B1 agonists 
can act in synergy to increase levels of prostanoids. This is also consistent with the results in 
this thesis because indomethacin blocked IL -lß induced hyperalgesia, the enhanced 
hyperalgesia observed following Bk, and the B1- mediated effects on neural discharge. 
However, in behavioural studies indomethacin did not block IL -13- induced B1- mediated 
hyperalgesia suggesting that other pathways can be involved. Another possibility are 
leukotrienes, in particular leukotriene B4 (LTB4) - a product of the lipoxygenase pathway 
which has been shown to sensitise nociceptors to mechanical and thermal stimulus (Martin et 
al., 1987). To study this, further experiments using inhibitors of 5- lipoxygenase, the enzyme 
responsible for generating leukotrienes from arachidonic acid, or specific leukotriene receptor 
antagonists. In recent years several 5- lipoxygense inhibitors and specific leukotriene 
antagonists have emerged. For example, zileuton (Abbot), a 5- lipoxygenase inhibitor (Rubin 
et al., 1991) or ONO -4057 (ONO Pharmaceuticals) and CGS- 25019C (Novartis), both LTB4 
antagonists (for review see Girard and Bonne, 1997) could be emplyed to test this hypothesis. 
With all the positive feedback loops occurring during inflammation (kinins releasing 
cytokines, cytokines enhancing responses to kinins and releasing further cytokines and both 
releasing prostanoids), it is not surprising that some negative feedback loops occur to 
autoregulate inflammation. The present studies have shown that endogenously released NO 
can inhibit neural discharge in nociceptors and can reduce Bk- induced activation of 
nociceptors in inflamed ankle joints. This is consistent with studies which have shown that 
NO is anti -nociceptive (Ferreira et al, 1991). Since kinins and IL -113 both induce the 
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production of NO, this may be one mechanism how inflammatory mediators reduce 
hyperalgesia associated with inflammation. The role of NO was not evaluated in arthritic 
knee joints, in which Bk responses had a tendency to be lower than those observed in normal 
knee joints. Thus it remains to be seen whether NO would have the same modulatory role in 
the knee joint or if this was an action peculiar to the inflamed ankle joint. 
This thesis also highlights the negative feedback role of two cytokines, IL -4 and IL -10, which 
are both present in elevated levels in the synovial fluid obtained from patients with 
rheumatoid arthritis, and which can be released by IL -113. In the present study IL -4 and IL -10 
both prevented the hyperalgesia induced by IL -113 and IL -1(3- induced kinin B I and B2 receptor 
mediated hyperalgesia. This is consistent with previous reports that IL -10 inhibited cytokine- 
mediated hyperalgesia in the rat paw (Poole et al., 1995). The exact mechanism by which IL- 
4 and IL -10 reduce hyperalgesia cannot be established from the experiments performed in this 
thesis. However, both have been show to inhibit IL -1 synthesis (Essner et al., 1989), to 
increase levels of IL -lra ( Vannier et al., 1992; Jenkins et al., 1994) and increase levels of the 
soluble IL -1RII `decoy receptor'(Colotta et al., 1993), all of which would reduce the effects 
of IL -113. Time constraints didn't permit evaluation of IL -4 and IL -10 in the 
electrophysiological experiments in this thesis, but it would obviously be of interest to study 
these in inflamed knee joints and could form the basis of exciting work in the future. 
In conclusion although the results of experiments performed in this thesis go some way to 
establishing the role of certain inflammatory mediators in inflammatory pain, it seems 
unlikely that a single mediator is solely responsible for the associated hyperalgesia in 
inflammatory conditions such as rheumatoid arthritis. The inflammatory process is very 
complex with a cornucopia of mediators released which interact with each other and many 
more experiments are clearly required to further elucidate the underlying role of these 
mediators in the hyperalgesia associated with inflammatory pain. Hopefully results from such 
studies will lead to future therapies for inflammatory conditions such as rheumatoid arthritis. 
The main clinical treatment for conditions such as rheumatoid arthritis still remains the non - 
steroidal anti -inflammatory drugs ( NSAIDS), these decrease the production of prostanoids by 
inhibiting their synthesis from arachidonic acid by inhibiting the COX enzyme. However, 
NSAIDS are not effective at alleviating the pain in all patients with rheumatoid arthritis and 
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often patients have periods of intense joint pain. There are other problems associated with 
inhibiting prostaglandin synthesis. Although NSAIDS may be effective at reducing the pain 
suffered by patients, they do not attenuate the on -going destruction of the joint, and so, leads 
to further irreversible damage to the joint. At the moment several pharmaceutical companies 
are researching new therapies to replace NSAIDS. The benefits of selective inhibitors of the 
inducible COX -2 enzyme, which have been shown to be anti -inflammatory without the typical 
side effects observed with COX -1 inhibitors, are being researched and developed for future 
use in the clinic (Talley, 1997), for example, celecoxib (Searle) (Hubbard et al., 1996) and 
MK -966 (rofecoxib, Merck) (Ehrich et al., 1996). Pharmaceutical companies are also actively 
considering the benefits of cytokine inhibitors including IL -1 receptor antagonists, interleukin 
converting enzyme inhibitors and anti -inflammatory cytokines for future clinical use in 
conditions such as rheumatoid arthritis, some of which are already undergoing clinical trials 
(for update see Earl, 1997). Orally active kinin receptor antagonists are also being researched 
and developed for future clinical use in conditions such as rheumatoid arthritis. 
Future experiments. 
As mentioned previously it is very difficult to ascertain the effects of antagonists on 
spontaneous (on- going) neural discharge in sensory nerves innervating inflamed knee joints. 
Further development of the rat knee joint model for recording from C- fibres is necessary, 
involving recording of mechanical- , or thermal- induced neural discharge in C- fibres which 
would be a closer correlate to the behavioural studies. Mechanical- induced effects on neural 
discharge have already been achieved in the cat knee joint (Schaible & Schmidt, 1983) where 
it was found that in inflamed joints normal physiological movement of the joint which would 
normally be non -noxious, induced activity in knee joint afferents. Although, the rat knee joint 
is much smaller than that in the cat, it seems possible that a movement -induced activaton of 
knee joint C- fibres could be achieved in this novel model. Indeed, pilot studies were carried 
out to see if this was possible and although technically more difficult, increases in neural 
discharge were observed following movement of the joint. However, further work should be 
carried out to enhance and improve the viability of such a model. If this was achieved the 
effects of antagonists could be studied, to test their behavioural anti -nociceptive actions in 
neural studies. 
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The main finding of this thesis has been that, in inflammation, kinin B 1 receptor agonists 
activate knee joint C -fibre nociceptors and induce a behavioural hyperalgesia. It seems likely 
that this is not via direct action via B1 receptors located on nociceptors, but by an indirect 
action via B1 receptors on inflammatory cells. It is not possible from the present results to 
establish the site of action of the B1 receptor agonists. Kinin B1 receptors have been shown to 
be present on macrophages, fibroblasts and synovial cells. Therefore, isolation and culture of 
the cells present within the knee joint following inflammation to investigate whether B1 
receptors are present on these cells should elucidate the site of action of B 1 receptor agonists 
in inflammatory hyperalgesia. It is possible to culture cells from synovial tissue and test 
whether these have B1 kinin receptors by auto -radiography or functional studies. 
The pain associated with inflammatory joint diseases, such as rheumatoid arthritis is literally 
crippling. Further studies like those suggested above are obviously worthwhile in attempting 
to improve our knowledge and understanding of the disorder and improve on existing 
treatments in the clinic. 
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